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Cocaine use has been linked to an increased risk of human papillomavirus (HPV) 
infection and cervical cancer among women, as well as immune suppressive effects in 
laboratory and animal settings. We hypothesized that cocaine may impact immune 
control and reduce the host’s ability to suppress HPV replication. However, the role of 
cocaine use on immunity has not yet been examined in drug-using populations at high 
risk for HPV infection and cervical cancer. Understanding the natural history of HPV 
infection in the context of potential cocaine-associated immune suppression may 
influence clinical management of drug-using women at risk for cervical cancer.  
Using human immunodeficiency virus (HIV)-infected and at-risk uninfected 
Women’s Interagency HIV Study (WIHS) participants followed prospectively prior to the 
widespread use of highly active antiretroviral therapy (HAART), we found nearly half 
exhibited a diminished epithelial immune response detected using cutaneous anergy 
testing. We observed a positive association between cocaine use and epithelial immune 
suppression independent of other risk factors among HIV-uninfected women. In contrast, 
we were unable to detect a cocaine effect on this immune-mediated response among 
women with immune-suppressive HIV infection.  
We additionally examined the association between cocaine use and incident 
cervical abnormalities detected by Papanicolau (Pap) smear testing among current and 
former injection drug-using women in the AIDS Linked to the Intravenous Experience 
(ALIVE) study. Stratifying our analyses by HIV status, we observed a non-statistically 
significant increased risk of incident abnormalities among HIV-uninfected women who 
recently used cocaine. Similar to the cocaine-anergy analysis, we also found no 
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association among HIV-infected women between cocaine use and abnormal Pap results. 
However, cervical abnormalities detected by Pap smear may reflect cellular changes not 
associated with risk of HPV-associated cervical cancer, warranting closer examination. 
We further examined the effect of cocaine use on HPV-specific cervical cytological 
abnormalities in a subset of women with HPV genotype data available, but were unable 
to detect statistically significant risk associations. 
Our findings among immune competent women indicate a potential association 
between cocaine use and dampened cell-mediated immunity at the epithelial cell level. 
Cocaine-mediated immune suppression may have direct implications for HPV-related 
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Human Papillomavirus (HPV) Infection and Cervical Cancer 
Papillomaviruses are small, double-stranded DNA viruses that encode only 8 or 9 
proteins. They have been in existence for 300 million years (1), and have evolved with 
their vertebrate hosts (1-4). Papillomaviruses are species-specific viruses, meaning that 
human papillomavirus (HPV) only infects humans, and also exhibit tissue tropism to 
squamous epithelia (5).  
More than 150 human papillomavirus genotypes have been identified, and they 
are classified by their epithelial tropisms. Beta, gamma, mu, and nu papillomaviruses 
infect cutaneous epithelial surfaces, but typically do not cause apparent infections in 
immunocompetent hosts. Alpha papillomaviruses can infect both mucosal and cutaneous 
epithelial surfaces. The viral life cycle of HPV is exclusively intraepithelial (6) and does 
not develop into a systemic infection. It also does not induce viremia or clinically evident 
inflammation upon initial infection (7, 8). Low-risk mucosal types are associated with 
genital warts. 
While most of these infections will remain subclinical for life, a subset of 
approximately 13-15 HPV genotypes can lead in rare cases to development of invasive 
cancer at the site of infection (9, 10). The cervix is most susceptible to HPV-mediated 
carcinogenesis, with 11,818 cases of cervical cancer occurring in 2010 in the United 
States (11). While 100% of all cervical cancer cases are attributable to HPV infection, 
proportions of other cancers attributable to HPV infection vary from 3% of mouth cancer, 
12% of oropharyngeal cancer, 40% of cancers of external genitalia (penile and 
vulvar/vaginal), to 90% of anal cancers (5, 12). Globally, the burden of cervical, penile, 
anal, vulvar/vaginal, mouth, and oropharyngeal cancers was estimated in 2002 to be over 
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5.8 million cases among males and over 5.06 million cases among females (12). High-
risk types 16 and 18 are estimated to cause nearly 72% of all cancers attributable to HPV 
and almost 70% of cervical cancer cases (12).   
Natural history of HPV 
Genital HPV infection is the most common sexually transmitted infection, with an 
estimated annual incidence of 6.2 million among persons aged 15 to 44 years in the 
United States (13). Studies have demonstrated that up to 80% of sexually active adults 
will acquire at least one HPV type infection during their lifetime (14). HPV infection 
affects 26.8% of women of reproductive age at any given time (15), and, generally, co-
infection with multiple HPV types is common (about half of all infections) (16).  
While HPV is highly prevalent, most HPV infections are transient in nature; 
typically, almost half of HPV infections will be cleared or controlled below the limit of 
detection within six months and 90% of HPV infections will become undetectable within 
two years of acquisition (17). Among women in the general population, following initial 
exposure, HPV establishes infection in the basal epithelial layer of the cervix, and is 
typically cleared or controlled by an intact immune system through cell-mediated 
immune responses within one to two years of initial infection (18-20); even high-risk 
type infections typically remain continuously detectable for 12 to 18 months (21). 
Whether the immunity is sterilizing (e.g., results in viral eradication) or merely controls 
virus below limits of detection, similar to other human DNA virus infections, remains 
unclear, though an increasing body of evidence supports the possibility of lifelong 
latency and immune control (22-25). 
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Of all HPV infections, approximately ten percent are persistently detectable for 
more than two years (26) and can cause cytological changes. In a large, multicenter study 
of U.S. women, while over 90% of prevalent HPV infections cleared within two years, 
the infections that persisted past 24 months were more likely to continue to persist (20). 
One explanation for this association may be that prevalent infections have successfully 
evaded the immune system in order to remain replicative and detectable, while incident 
infection may reflect new acquisition (27). High-risk HPV types are more likely to persist 
than low-risk types, and are more likely to be associated with risk of higher-grade 
cervical lesions (17). These persistent infections need careful clinical management, 
including follow-up and treatment, to prevent cervical cancer. 
Natural history of cervical intraepithelial neoplasia (CIN) 
 Cervical cytologic abnormalities are classified by histology and by cytology using 
standard nomenclature to describe the severity of cellular changes induced by HPV 
infection and HPV-mediated cellular transformation. The nomenclature varies depending 
on whether cytological examination of exfoliated cells or histological examination of 
tissue sections is performed. Histology, based on examination of biopsied cervical tissue, 
is assigned according to range of cellular atypia confined to the epithelium and termed 
cervical intraepithelial neoplasia (CIN). CIN is classified according to level of dysplasia 
observed in the tissue sample, from mild (CIN 1), moderate (CIN2), to severe (CIN 3), 
which are considered high-grade precursors to invasive cervical cancer (28). Squamous 
intraepithelial lesions (SIL) are detected by cytologic Papanicolau (Pap) smear, a clinical 
method of cervical cancer screening where cervical cells are sampled, examined under 
magnification, and classified based on the presence or absence of cellular abnormalities 
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using standardized terminology according to the Bethesda System (29, 30). Using the 
Bethesda System, cervical lesions are divided into two grades: low-grade SIL (LSIL) 
which consists of flat condylomatous changes (indicating HPV presence) and high-grade 
SIL (HSIL) which are defined as more severe neoplastic lesions (30, 31). The severity of 
HPV-mediated cell changes from normal cervical epithelium to invasive cervical cancer 
may be described using either cytology or histology; Figure 1 displays the relationship 
and overlap between the two classification systems, where LSIL is equivalent to mild 
CIN, or CIN 1, and HSIL may be CIN 2 or CIN 3, and describes the cellular changes that 
lead to invasive cervical cancer (32). In brief, HPV initially infects the basal epithelial 
cells through micro-abrasions or micro-trauma. Viral replication occurs within these 
basal cells undergoing active cell division; the cytopathic changes that become detectable 
including koilocytosis, multinucleation, and nuclear enlargement reflect the viral 
replication occurring in the upper epithelial layer of cells (33). As the upper epithelium is 
shed, HPV is released and can start a new infection in another host. The cytopathic 
changes due to productive HPV replication are detected as low-grade squamous 
intraepithelial lesions, or LSIL (34) and are consistent with CIN1. A small proportion of 
high-risk HPV infections will persist and cause more severe cytological changes termed 
high-grade SIL, or HSIL, and is equivalent to CIN grade 2 and 3 (CIN2, CIN3). Finally, 
the last and uncommon step to invasive cervical cancer is the progression of HSIL or 
CIN3, which is frequently but not always associated with integration of the HPV genome 
into host chromosomes (35, 36). 
 Pap smear tests have been in widespread use for the past few decades in screening 
programs in the United States to detect early precancerous cervical lesions and thus 
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prevent invasive cervical cancer (37). Over 60 million Pap tests are performed annually 
in the United States (16), and prior studies have determined the proportion of various 
cytological diagnoses that were HPV positive: 49% of ASCUS, 83% of LSIL, and 92% 
of HSIL (CIN2+) in a U.S. multicenter, community-based population (38); 70% of LSIL, 
89% of HSIL in a northern California cohort (39); and high-risk HPV type positive for 
66% of CIN1, 83% of CIN2, 93% of CIN3 in a U.S. multicenter screening population 
(40). Increasing severity of clinical disease tends to reflect increases in proportion of 
HPV-positive results. Other abnormal cytology results involve glandular cells instead of 
epithelial cells, and include diagnoses of atypical glandular cells (AGC), AGC favor 
neoplasia, and endocervical adenocarcinoma in situ (AIS), which are frequently due to 
benign conditions, but can also be associated with neoplasia and cervical cancer (16).  
 The majority (~90%) of abnormal Pap diagnoses represent minimally abnormal 
changes associated with HPV infection (e.g., atypical squamous cells of undetermined 
significance (ASCUS) and LSIL). Clinical management of abnormal Pap results follows 
a logic of “equal management of equal risks” based on data on cervical precancer 
management from a very large cohort of nearly one million women in an integrated 
health care system followed for over nine years (41). Abnormal Pap results of ASCUS in 
the absence of HPV testing are followed by repeat cytology one year later (42), as the 
estimated risk of CIN3+ (as a marker of pre-cancer) is very low (around 2.6%) among 
these women (41). If ASCUS Pap results are followed with HPV co-testing, and a woman 
is found to be ASCUS-positive and HPV-negative, the American Society for Colposcopy 
and Cervical Pathology (ASCCP) recommends extending the repeat Pap and HPV co-test 
interval to three years for these low-risk women (42).  
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Low-grade lesions, LSIL or CIN1, represent productive HPV infection, are 
usually self-limited, and will regress without any treatment (43, 44). However, based on 
recent research (41), the five-year risk of CIN3+ is 5.2% when LSIL is detected; thus, 
findings of LSIL-positive/HPV-positive and LSIL-positive/HPV-unknown are both 
managed with immediate colposcopy. In addition, a positive HPV co-test result with 
ASCUS Pap finding confers 6.8% risk of CIN3+, which is greater than the 5.2% risk 
estimated with a LSIL Pap result (41); therefore, the ASCCP also recommends 
management using immediate colposcopy (42), the typical management strategy when 
LSIL is detected.  
A small subset of SIL will progress to invasive cancer over an average of ten to 
15 years (45-47). In the Kaiser Permanente Northern California cohort, there was 30-49% 
risk of progression from to CIN3+ within five years when HSIL was detected on Pap 
smear (48). As a result, detection of HSIL on a Pap test will prompt immediate excision 
or colposcopy (42, 48). These HSIL+ and CIN2+ are the targets of cervical cancer 
screening, as excisional removal of these lesions is relatively simple and treatment has 
>90% success rate (49, 50).  
Critical role of host immunity on HPV and CIN natural history 
It is clear that the nature of the host immune response to HPV infection plays a 
crucial role in determining which infections develop into long-term persistent infections 
with higher risk of progression to neoplasia and cancer. The clearance or control of the 
majority (80-90%) of HPV infections is thought to be facilitated by CD4+ T cell 
dependent mechanisms, based largely on observations of intraepithelial infiltrates 
observed during lesion resolution in animal papillomavirus models (51-53). In samples of 
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varying severity of cervical intraepithelial neoplasia, it has been shown that the density of 
T cell lymphocytes may play an important role on risk of progression and regression of 
cervical lesions (54).  
In addition to the evidence provided by animal and tissue models, the higher risk 
of persistent HPV infection, incident HPV infection, and disease progression observed in 
immune-suppressed populations further support the critical role of host immune response 
in HPV-associated disease risk. For example, HPV-associated neoplasias have been 
commonly reported among immunosuppressed transplant recipients (55-58) and 
incidence of HPV-associated cancers are increased in transplant patients (59). Since 
transplant recipients are iatrogenically immune-suppressed to prevent rejection of the 
transplanted organ, it is likely that immune suppression drives HPV persistence and 
increased cervical cancer risk in this context. Among aging populations, immune 
senescence is suggested to play a role in HPV persistence (23, 60); the increased risk of 
HPV-associated outcomes may be explained by waning immunity and inability to 
maintain control of HPV replication.  
Further support for an immunologic role in the natural history of HPV infection 
comes from the epidemiologic association of HIV infection with higher prevalence and 
incidence of HPV infection and related cervical disease (61-63). Among HIV-
immunosuppressed populations, there is a disproportionate increase in the prevalence of 
low-grade lesions (62, 64-66), suggesting that immune suppression may increase the risk 
of clinical evidence of HPV infection and persistence. Epidemiologic studies measuring 
HPV incidence, prevalence, and persistence have reported a dose-response relationship 
with increasing immune suppression, measured by both decreasing systemic CD4 count 
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and increasing systemic HIV viral load (67-70), and increasing severity of HPV-
associated clinical disease (71-73). In the Women’s Interagency HIV Study (WIHS), a 
natural history study conducted among HIV-infected and at-risk HIV-uninfected women 
in the United States, HIV-related immune markers like serostatus, CD4 cell count, and 
HIV RNA level were found to be associated with abnormal Pap results (74, 75). Infection 
with multiple HPV types is also more common among HIV-infected populations 
compared to their uninfected counterparts (76), and, among HIV-positives, multiple type 
infection is more common with decreasing CD4 cell count (77), offering further support 
for the critical role of intact cell-mediated immunity in the control of HPV infection. 
Cervical cancer, representing the fulminant clinical endpoint of uncontrolled, persistent 
HPV infection, has also been reported to be higher among HIV-infected women, 
especially those who are severely immunosuppressed (78-80).  
Local genital tract immune responses may be even more critical in the control of 
HPV infections and prevention of disease progression than systemic immune responses. 
Most of the markers of immune suppression in HIV-infected women are based on 
systemic measures of immune response. Conversely, HPV infection has no systemic 
phase (6) and it is likely that the local cervical immune microenvironment plays a critical 
role in shaping the immune response to HPV infection. Direct measures of HPV-specific 
cell-mediated immunity are currently unavailable (81); however, more global measures 
of epithelial immune suppression have been associated with an increased risk of incident 
HR-HPV detection and prevalent SIL(82). These studies measured T-cell-dependent 
immune response in the cutaneous epithelium by challenging the participant with 
common antigens (e.g., Candida albicans, tetanus toxoid, and mumps) injected 
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intradermally on the forearm using the Mantoux method (82, 83). The size of induration, 
defined as the hard, dense, raised formation just under the skin surface formed by the 
recruitment of macrophages, monocytes, lymphocytes, and other cellular components by 
memory T cells in reaction to the antigens, determines the level of delayed type 
hypersensitivity (DTH) response and is measured between 48 to 72 hours following 
administration (84-86). Most manufacturers suggest induration of 5mm or greater as the 
definition of a “positive” test, representing “normal” DTH function. Since intact cell-
mediated immunity (CMI) involves interactions between lymphocytes, macrophages, and 
cytokines, anergy testing serves as an in vivo clinical test to measure the functional 
presence of T-cell immune competence at the epithelial surface (87). Lack of an adequate 
immune response to the injected antigens results in anergy (84).  
In the WIHS, associations between anergy and both prevalent lesions and incident 
high-risk HPV held even after the investigators adjusted for systemic markers of HIV-
associated immune status (e.g., HIV-RNA level and CD4 T-cell strata) (82), supporting 
the possibility that local cell-mediated immunity is involved in the control of HPV 
infection. However, the antigens tested were not HPV antigens, and more direct measures 
of cervical immune responses are needed to confirm the potential association of local 
immune control of HPV infection.  
Indirect evidence for the role of the cervical immune microenvironment in 
controlling cervical HPV infection also comes from the examination of women during 
acute HIV infection, which is known to be associated with a profound loss of CD4 
memory at mucosal sites. Two studies have shown that women in this early phase of HIV 
infection have increased risk of multiple new HPV type infection, further supporting the 
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notion that local immunologic control of latent HPV infection is a primary regulator of 
HPV natural history (88, 89).  
In addition to HIV co-infection, which is highly immune suppressive, other risk 
factors associated with HPV persistence and cervical cancer have been shown to have 
immune suppressive functions, including smoking (90), oral contraceptive (OC) use (91-
93), and parity (94, 95). Smoking has been identified in many epidemiologic studies as a 
risk factor for prevalent (96) and incident HPV (96), CIN3+ (97), and cervical cancer (58, 
90, 94, 98). Local cell-mediated immune suppression has been suggested to explain the 
link between tobacco smoking and increased HPV infection and cervical cancer (94, 99). 
Parity has been hypothesized to be associated with increased risk through various 
mechanisms including an immunologic pathway; it is thought that pregnancy-induced 
hormonal changes may alter the immune response to HPV and increase risk of 
persistence and progression (94, 95). Hormonal modulation of host immunity may also 
contribute to increased risk of HPV persistence (93), HSIL, and cervical cancer among 
women who have used OC’s for an extended period, usually longer than five years (94), 
although the biological mechanism has not yet been elucidated. Taken together, these 
findings lend support for an immune suppressive pathway leading to increased risk of 
HPV persistence and associated lesions, and indicate the importance of determining 
whether other risk groups, such as drug users, are at increased risk for HPV and 
associated disease through a similar immunologic mechanism. 
Illicit drug use and HPV/CIN risk 
Use of illicit drugs may be potentially useful as a risk stratifier to identify 
populations likely to progress more rapidly to advanced stage disease and to target 
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appropriately with screening and treatment to prevent cervical cancer. Prior studies have 
identified injection drug use, particularly use of cocaine, as a risk factor for HPV 
infection among both HIV-seropositive and HIV-seronegative women (100, 101). Higher 
frequency of invasive cervical cancer has been observed among IDUs (102). Table 1 
illustrates the overall findings from seven epidemiologic studies published in the past 18 
years that evaluated the association between illicit drug use and HPV and associated 
disease outcomes. Overall, the existing literature is consistent with an increased risk of 
HPV infection and related clinical outcomes among populations who use illicit drugs, 
with estimates of association ranging in magnitude from odds ratios of 1.3 to 2.2 for HPV 
infection (100, 101, 103) to over two-fold increases for Pap abnormalities among HIV 
immunosuppressed (CD4<200) recent crack cocaine users (100) and drug users (104). 
Cervical cancer risk among drug users has also been observed to be elevated (79, 102, 
104, 105). However, the majority of these epidemiologic studies have defined drug 
exposures broadly as being an injection drug user or having drug addiction, (79, 102-
105), making it difficult to infer effects of exposure to specific drugs. Prior research has 
also been hampered by insufficient control of potential confounders, including not 
accounting for sexual risk behavior (103, 105), presenting only unadjusted analyses 
(104), as well as defining the drug exposure using non-specific measures like diagnostic 
codes from inpatient admissions (105). Few studies were prospectively designed and 
included relevant measures of potential confounders to appropriately examine the 
relationship between cocaine use and HPV infection and related outcomes.  
Published literature to date has supported two potential mechanisms to explain the 
association between drug use and HPV infection: direct effects of illicit drug exposures 
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and the indirect effects of sexual behaviors that are associated with both illicit drug use 
and HPV infection (34, 106). However, the limited body of literature has not yet 
identified the pathway to explain the link.  
  Since injection drug use is associated with increases in risky sexual behavior 
(107, 108), the observed association with HPV infection may merely result from 
confounding by high-risk sexual behavior. However, three studies have also suggested 
that sexual behavior including, but not limited to, recent (i.e., in last six months) and 
lifetime number of male partners (100, 101) and prostitution (102) does not completely 
explain the association between drug use and HPV-associated outcomes. Since the 
associations between HPV infection and drug use were not substantially attenuated after 
adjustment for several markers of sexual activity and sexual risk (100), we cannot rule 
out the possibility that the observed effect may in fact have a biological basis.  
 Evidence supporting a biological mechanism of drug-induced immune 
suppression originates at the cellular level. Cocaine is a sigma-ligand agonist and is 
known to induce immune suppression through suppressing proliferation of lymphocytes, 
including alteration of natural killer cell, helper T cell (CD4+), and cytotoxic T cell 
(CD8+) activity, as well as neutrophil and macrophage activity as the first line of defense 
against infection (109). There is convincing laboratory evidence for immune suppressive 
effects caused by cocaine exposure including a potential cocaine-facilitated switch to a 
Th2 anti-inflammatory immune response associated with increased susceptibility to 
infection with bacteria, protozoa, and viruses (110). Anti-HPV effector T cells prevent 
growth of HPV-associated tumors in various animal models (111) and a Th2 immune 
response with low levels of IFN-gamma and increased IL-10 production fails to protect 
 14 
and control HPV infection and its oncogenic effects, including in vivo tumor growth 
(110). Additional immune suppressive effects associated with cocaine exposure include 
reduced delayed-type hypersensitivity (DTH) response and reduced effector cell 
proliferation (112).   
 In addition to in vitro studies, animal models demonstrate additional support for 
cocaine-induced immune suppression specific to mucosal and epithelial sites, which may 
have a direct impact on epithelia-tropic HPV. Murine models have shown cocaine 
exposure to be associated with a decrease in IgA+ cells and an increase in number of 
CD8+ cells in the intestinal lamina propria, suggesting injury to mucosal immunity (113). 
Oral cocaine administration appears to inhibit cell-mediated immunity at epithelial 
surfaces, as measured by the DTH response to dinitrofluorobenzene (DNFB) in the 
mouse model (114). Repeated daily injection of cocaine in the mouse model induced a 
diminished DTH reaction and a slight decrease in IgG levels, suggesting reduced mucosal 
immunity associated with chronic cocaine exposure (115).  
Despite growing evidence for the immunosuppressive effects of illicit drugs like 
cocaine in animal and in vitro studies, there is a lack of longitudinal epidemiologic 
studies to demonstrate the effect of cocaine and other illicit drugs on increased incidence 
of infections in humans (110, 112, 116). The only large epidemiologic studies that have 
examined drug use and HPV are two prospective cohort studies among women with HIV 
infection or at high-risk for HIV infection as a result of injection drug use or who were 
current or former injection drug users, the WIHS and ALIVE studies, have evaluated the 
association between drug use and HPV and associated disease outcomes (100, 101). In 
these studies, recent (defined as occurring within the previous six months) crack/cocaine 
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use was associated with a 1.7 fold-increased risk of new HPV infection in the ALIVE 
cohort (100) and 1.3 fold-increased risk of oncogenic HPV type infection in the WIHS 
cohort (101). In the WIHS, increased risk of oncogenic HPV-positive cervical lesions 
was also observed among crack/cocaine users (OR 1.70, 95% C.I.: 1.27-2.27) (101). In 
the ALIVE study, an increased risk of Pap abnormality was observed only among the 
most severely immune suppressed HIV-infected women (OR 2.4, 95% C.I: 1.1-5.1) 
(100)who recently used crack cocaine. However, this prior analysis was limited to a 
subset of the overall cohort enrolled in a gynecological sub-study and to only five years 
of follow-up time. Evidence supporting cocaine-induced immune suppression has been 
reported among HIV-infected drug users, where both persistent and intermittent crack 
cocaine (a crystallized form of cocaine that is taken by inhalation) users were more likely 
than non-users to develop new AIDS-defining illnesses, as well as lower CD4 counts and 
higher HIV-1 RNA levels (117), suggesting that concurrent crack use may accelerate 
HIV-mediated immune suppression. Understanding the relationship between cocaine 
exposure and immune suppression still requires further examination in larger cohorts of 
drug using women with longer follow-up.  
Conceptual Framework 
In summary, HPV infection has been found to be associated with both cutaneous 
anergy and cocaine/crack use, independent of sexual behavior and HIV-related immune 
markers (HIV RNA levels and CD4 counts). Since animal and tissue models have shown 
that use of illicit drugs modulates the immune response, which may result in anergy, we 
hypothesize that the association between cocaine/crack use and HPV is mediated by 
drug-induced reduction in DTH response. 
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The analyses conducted in this dissertation will allow direct assessment of the 
association between cocaine use and cutaneous anergy as a marker of impaired epithelial 
cell-mediated immune response, and will explore whether cocaine use is associated with 
increases in HPV-associated cervical cytological abnormalities. Figure 2 shows the 
fundamental conceptual framework in which we examine associations between use of 
cocaine and HPV. We test the hypothesis that the use of crack/cocaine is associated with 
dampened local epithelial immunity, measured by the absence of a DTH response using 
the cutaneous anergy skin test (Chapter Two). Additionally, there is some evidence that, 
among injection drug using populations, exposure to cocaine/crack cocaine may be 
associated with increased HPV infection (100). To better understand this purported 
relationship, we extend the previous analyses in a current and former drug-using 
community-based cohort with over 18 years of follow-up to examine the association 
between cocaine use and clinically detectable HPV infection (Chapter Three).  
Analysis/Specific Aims 
In order to advance our understanding of the relationships between HPV, immune 
status, and cocaine use among women with HIV or at high-risk of acquiring HIV, we 
reviewed relevant literature and conducted the following analyses: 
1. We examined the association between recent use of cocaine and incident HPV-
associated cytological abnormalities in an urban-dwelling cohort of former and 
current injection drug using women with and without HIV infection.  
2. We evaluated whether an immunosuppressive pathway might explain the high 
rate of HPV-associated outcomes among drug users by assessing the relationship 
 17 
between cocaine use and a measure of delayed-type hypersensitivity immune 
responsiveness, cutaneous anergy, in a longitudinal, urban cohort of HIV-infected 
and –uninfected women across the United States.  
 18 
Figure 1. HPV-mediated progression to cervical cancer 
 
Source: Woodman et al. Nature Reviews Cancer 7, 11-22 (January 2007) 
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Figure 2. Conceptual Framework for the Associations between Cocaine Use, Immune 
suppression, and HPV infection 
Drug Use 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1. Burk RD, Harari A, Chen Z. Human papillomavirus genome variants. Virology. 
2013;445(1-2):232-43. 
2. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. 
Classification of papillomaviruses (PVs) based on 189 PV types and proposal of 
taxonomic amendments. Virology. 2010;401(1):70-9. 
3. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification 
of papillomaviruses. Virology. 2004;324(1):17-27. 
4. Gottschling M, Goker M, Stamatakis A, Bininda-Emonds OR, Nindl I, Bravo IG. 
Quantifying the phylodynamic forces driving papillomavirus evolution. Molecular 
biology and evolution. 2011;28(7):2101-13. 
5. Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol 
Oncol. 2010;117(2 Suppl):S5-10. 
6. Stanley MA. Epithelial cell responses to infection with human papillomavirus. 
Clinical microbiology reviews. 2012;25(2):215-22. 
7. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al. The biology 
and life-cycle of human papillomaviruses. Vaccine. 2012;30 Suppl 5:F55-70. 
8. Einstein MH, Schiller JT, Viscidi RP, Strickler HD, Coursaget P, Tan T, et al. 
Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet 
Infect Dis. 2009;9(6):347-56. 
9. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et 
al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J 
Pathol. 1999;189(1):12-9. 
10. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. 
Epidemiologic classification of human papillomavirus types associated with cervical 
cancer. N Engl J Med. 2003;348(6):518-27. 
11. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–
2010 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health 
and Human Services, Centers for Disease Control and Prevention, and National Cancer 
Institute; 2013. Available at: http://www.cdc.gov/uscs. 
12. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 
2006;24 Suppl 3:S3/11-25. 
13. Weinstock H, Berman S, Cates W, Jr. Sexually transmitted diseases among 
American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 
2004;36(1):6-10. 
14. Brown DR, Shew ML, Qadadri B, Neptune N, Vargas M, Tu W, et al. A 
longitudinal study of genital human papillomavirus infection in a cohort of closely 
followed adolescent women. J Infect Dis. 2005;191(2):182-92. 
15. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. 
Prevalence of HPV infection among females in the United States. Jama. 
2007;297(8):813-9. 
16. Wheeler CM. Natural history of human papillomavirus infections, cytologic and 
histologic abnormalities, and cancer. Obstet Gynecol Clin North Am. 2008;35(4):519-36; 
vii. 
 24 
17. Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, 
et al. Updating the natural history of human papillomavirus and anogenital cancers. 
Vaccine. 2012;30 Suppl 5:F24-33. 
18. Trottier H, Franco EL. The epidemiology of genital human papillomavirus 
infection. Vaccine. 2006;24 Suppl 1:S1-15. 
19. Richardson H, Kelsall G, Tellier P, Voyer H, Abrahamowicz M, Ferenczy A, et 
al. The natural history of type-specific human papillomavirus infections in female 
university students. Cancer epidemiology, biomarkers & prevention : a publication of the 
American Association for Cancer Research, cosponsored by the American Society of 
Preventive Oncology. 2003;12(6):485-90. 
20. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM, Group 
A. A 2-year prospective study of human papillomavirus persistence among women with a 
cytological diagnosis of atypical squamous cells of undetermined significance or low-
grade squamous intraepithelial lesion. J Infect Dis. 2007;195(11):1582-9. 
21. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Desy M, et al. 
Epidemiology of acquisition and clearance of cervical human papillomavirus infection in 
women from a high-risk area for cervical cancer. J Infect Dis. 1999;180(5):1415-23. 
22. Gravitt PE. Evidence and impact of human papillomavirus latency. The open 
virology journal. 2012;6:198-203. 
23. Gonzalez P, Hildesheim A, Rodriguez AC, Schiffman M, Porras C, Wacholder S, 
et al. Behavioral/lifestyle and immunologic factors associated with HPV infection among 
women older than 45 years. Cancer Epidemiol Biomarkers Prev. 2010;19(12):3044-54. 
24. Doorbar J. Latent papillomavirus infections and their regulation. Current opinion 
in virology. 2013;3(4):416-21. 
25. Strickler HD, Burk RD, Fazzari M, Anastos K, Minkoff H, Massad LS, et al. 
Natural history and possible reactivation of human papillomavirus in human 
immunodeficiency virus-positive women. J Natl Cancer Inst. 2005;97(8):577-86. 
26. Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol Oncol. 
2008;109(2 Suppl):S15-21. 
27. Rodriguez AC, Schiffman M, Herrero R, Hildesheim A, Bratti C, Sherman ME, et 
al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial 
neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst. 
2010;102(5):315-24. 
28. Wright TC, Jr., Denny L, Kuhn L, Goldie S. Use of visual screening methods for 
cervical cancer screening. Obstet Gynecol Clin North Am. 2002;29(4):701-34. 
29. Tiro JA, Saraiya M, Jain N, Liddon N, Cokkinides V, Lai SM, et al. Human 
papillomavirus and cervical cancer behavioral surveillance in the US. Cancer. 
2008;113(10 Suppl):3013-30. 
30. Solomon D. The Bethesda System for reporting cervical/vaginal cytologic 
diagnosis: an overview. Int J Gynecol Pathol. 1991;10(4):323-5. 
31. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 
2001 Bethesda System: terminology for reporting results of cervical cytology. Jama. 
2002;287(16):2114-9. 
32. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV 
infection: unresolved issues. Nat Rev Cancer. 2007;7(1):11-22. 
 25 
33. Erickson BK, Alvarez RD, Huh WK. Human papillomavirus: what every provider 
should know. Am J Obstet Gynecol. 2013;208(3):169-75. 
34. Steben M, Duarte-Franco E. Human papillomavirus infection: epidemiology and 
pathophysiology. Gynecol Oncol. 2007;107(2 Suppl 1):S2-5. 
35. Vinokurova S, Wentzensen N, Kraus I, Klaes R, Driesch C, Melsheimer P, et al. 
Type-dependent integration frequency of human papillomavirus genomes in cervical 
lesions. Cancer Res. 2008;68(1):307-13. 
36. Melsheimer P, Vinokurova S, Wentzensen N, Bastert G, von Knebel Doeberitz 
M. DNA aneuploidy and integration of human papillomavirus type 16 e6/e7 oncogenes in 
intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri. 
Clinical cancer research : an official journal of the American Association for Cancer 
Research. 2004;10(9):3059-63. 
37. Datta SD, Koutsky LA, Ratelle S, Unger ER, Shlay J, McClain T, et al. Human 
papillomavirus infection and cervical cytology in women screened for cervical cancer in 
the United States, 2003-2005. Ann Intern Med. 2008;148(7):493-500. 
38. Group A-LTS. Results of a randomized trial on the management of cytology 
interpretations of atypical squamous cells of undetermined significance. Am J Obstet 
Gynecol. 2003;188(6):1383-92. 
39. Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, et 
al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing 
for equivocal Papanicolaou results. JAMA. 1999;281(17):1605-10. 
40. Wright TC, Jr., Stoler MH, Behrens CM, Apple R, Derion T, Wright TL. The 
ATHENA human papillomavirus study: design, methods, and baseline results. Am J 
Obstet Gynecol. 2012;206(1):46 e1- e11. 
41. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. 
Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into 
cervical screening and management guidelines. J Low Genit Tract Dis. 2013;17(5 Suppl 
1):S28-35. 
42. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 
2012 updated consensus guidelines for the management of abnormal cervical cancer 
screening tests and cancer precursors. J Low Genit Tract Dis. 2013;17(5 Suppl 1):S1-
S27. 
43. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of 
cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol. 1998;92(4 Pt 
2):727-35. 
44. Winer RL, Kiviat NB, Hughes JP, Adam DE, Lee SK, Kuypers JM, et al. 
Development and duration of human papillomavirus lesions, after initial infection. J 
Infect Dis. 2005;191(5):731-8. 
45. Vink MA, Bogaards JA, van Kemenade FJ, de Melker HE, Meijer CJ, Berkhof J. 
Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time 
to preclinical cervical cancer from doubly censored national registry data. Am J 
Epidemiol. 2013;178(7):1161-9. 
46. van Oortmarssen GJ, Habbema JD. Duration of preclinical cervical cancer and 
reduction in incidence of invasive cancer following negative pap smears. Int J Epidemiol. 
1995;24(2):300-7. 
 26 
47. Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine 
cervix. J Natl Cancer Inst. 1999;91(3):252-8. 
48. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. 
Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and 
HPV-negative high-grade Pap results. J Low Genit Tract Dis. 2013;17(5 Suppl 1):S50-5. 
49. Nuovo J, Melnikow J, Willan AR, Chan BK. Treatment outcomes for squamous 
intraepithelial lesions. International journal of gynaecology and obstetrics: the official 
organ of the International Federation of Gynaecology and Obstetrics. 2000;68(1):25-33. 
50. Wright TC, Jr., Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D, et 
al. 2006 consensus guidelines for the management of women with cervical intraepithelial 
neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol. 2007;197(4):340-5. 
51. Nicholls PK, Klaunberg BA, Moore RA, Santos EB, Parry NR, Gough GW, et al. 
Naturally occurring, nonregressing canine oral papillomavirus infection: host immunity, 
virus characterization, and experimental infection. Virology. 1999;265(2):365-74. 
52. Nicholls PK, Moore PF, Anderson DM, Moore RA, Parry NR, Gough GW, et al. 
Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ 
lymphocytes. Virology. 2001;283(1):31-9. 
53. Wilgenburg BJ, Budgeon LR, Lang CM, Griffith JW, Christensen ND. 
Characterization of immune responses during regression of rabbit oral papillomavirus 
infections. Comparative medicine. 2005;55(5):431-9. 
54. Monnier-Benoit S, Mauny F, Riethmuller D, Guerrini JS, Capilna M, Felix S, et 
al. Immunohistochemical analysis of CD4+ and CD8+ T-cell subsets in high risk human 
papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix. 
Gynecol Oncol. 2006;102(1):22-31. 
55. Hinten F, Meeuwis KA, van Rossum MM, de Hullu JA. HPV-related 
(pre)malignancies of the female anogenital tract in renal transplant recipients. Critical 
reviews in oncology/hematology. 2012;84(2):161-80. 
56. Halpert R, Fruchter RG, Sedlis A, Butt K, Boyce JG, Sillman FH. Human 
papillomavirus and lower genital neoplasia in renal transplant patients. Obstet Gynecol. 
1986;68(2):251-8. 
57. Schneider V, Kay S, Lee HM. Immunosuppression as a high-risk factor in the 
development of condyloma acuminatum and squamous neoplasia of the cervix. Acta 
Cytol. 1983;27(3):220-4. 
58. Dugue PA, Rebolj M, Garred P, Lynge E. Immunosuppression and risk of 
cervical cancer. Expert review of anticancer therapy. 2013;13(1):29-42. 
59. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in 
people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-
analysis. Lancet. 2007;370(9581):59-67. 
60. Garcia-Pineres AJ, Hildesheim A, Herrero R, Trivett M, Williams M, Atmetlla I, 
et al. Persistent human papillomavirus infection is associated with a generalized decrease 
in immune responsiveness in older women. Cancer Res. 2006;66(22):11070-6. 
61. Ho GY, Burk RD, Fleming I, Klein RS. Risk of genital human papillomavirus 
infection in women with human immunodeficiency virus-induced immunosuppression. 
Int J Cancer. 1994;56(6):788-92. 
62. Duerr A, Kieke B, Warren D, Shah K, Burk R, Peipert JF, et al. Human 
papillomavirus-associated cervical cytologic abnormalities among women with or at risk 
 27 
of infection with human immunodeficiency virus. Am J Obstet Gynecol. 
2001;184(4):584-90. 
63. Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC, Jr. Human 
papillomavirus infection in women infected with the human immunodeficiency virus. N 
Engl J Med. 1997;337(19):1343-9. 
64. Massad LS, Ahdieh L, Benning L, Minkoff H, Greenblatt RM, Watts H, et al. 
Evolution of cervical abnormalities among women with HIV-1: evidence from 
surveillance cytology in the women's interagency HIV study. J Acquir Immune Defic 
Syndr. 2001;27(5):432-42. 
65. Massad LS, Riester KA, Anastos KM, Fruchter RG, Palefsky JM, Burk RD, et al. 
Prevalence and predictors of squamous cell abnormalities in Papanicolaou smears from 
women infected with HIV-1. Women's Interagency HIV Study Group. J Acquir Immune 
Defic Syndr. 1999;21(1):33-41. 
66. Wright TC, Jr., Koulos J, Schnoll F, Swanbeck J, Ellerbrock TV, Chiasson MA, 
et al. Cervical intraepithelial neoplasia in women infected with the human 
immunodeficiency virus: outcome after loop electrosurgical excision. Gynecol Oncol. 
1994;55(2):253-8. 
67. Heard I, Tassie JM, Schmitz V, Mandelbrot L, Kazatchkine MD, Orth G. 
Increased risk of cervical disease among human immunodeficiency virus-infected women 
with severe immunosuppression and high human papillomavirus load(1). Obstet Gynecol. 
2000;96(3):403-9. 
68. Ahdieh L, Klein RS, Burk R, Cu-Uvin S, Schuman P, Duerr A, et al. Prevalence, 
incidence, and type-specific persistence of human papillomavirus in human 
immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis. 
2001;184(6):682-90. 
69. Zeier MD, Botha MH, van der Merwe FH, Eshun-Wilson I, van Schalkwyk M, la 
Grange M, et al. Progression and persistence of low-grade cervical squamous 
intraepithelial lesions in women living with human immunodeficiency virus. J Low Genit 
Tract Dis. 2012;16(3):243-50. 
70. Nappi L, Carriero C, Bettocchi S, Herrero J, Vimercati A, Putignano G. Cervical 
squamous intraepithelial lesions of low-grade in HIV-infected women: recurrence, 
persistence, and progression, in treated and untreated women. European journal of 
obstetrics, gynecology, and reproductive biology. 2005;121(2):226-32. 
71. Boardman LA, Cotter K, Raker C, Cu-Uvin S. Cervical intraepithelial neoplasia 
grade 2 or worse in human immunodeficiency virus-infected women with mildly 
abnormal cervical cytology. Obstet Gynecol. 2008;112(2 Pt 1):238-43. 
72. Cohn JA, Gagnon S, Spence MR, Harrison DD, Kluzak TR, Langenberg P, et al. 
The role of human papillomavirus deoxyribonucleic acid assay and repeated cervical 
cytologic examination in the detection of cervical intraepithelial neoplasia among human 
immunodeficiency virus-infected women. Cervical Disease Study Group of the American 
Foundation for AIDS Research Community Based Clinical Trials Network. Am J Obstet 
Gynecol. 2001;184(3):322-30. 
73. Johnson JC, Burnett AF, Willet GD, Young MA, Doniger J. High frequency of 
latent and clinical human papillomavirus cervical infections in immunocompromised 
human immunodeficiency virus-infected women. Obstet Gynecol. 1992;79(3):321-7. 
 28 
74. Minkoff H, Ahdieh L, Massad LS, Anastos K, Watts DH, Melnick S, et al. The 
effect of highly active antiretroviral therapy on cervical cytologic changes associated 
with oncogenic HPV among HIV-infected women. Aids. 2001;15(16):2157-64. 
75. Massad LS, Xie X, Minkoff H, Darragh TM, D'Souza G, Sanchez-Keeland L, et 
al. Abnormal Pap Tests and Human Papillomavirus Infections Among HIV-Infected and 
Uninfected Women Who Have Sex With Women. J Low Genit Tract Dis. 2013. 
76. Palefsky JM, Minkoff H, Kalish LA, Levine A, Sacks HS, Garcia P, et al. 
Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 
(HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst. 1999;91(3):226-
36. 
77. Strickler HD, Palefsky JM, Shah KV, Anastos K, Klein RS, Minkoff H, et al. 
Human papillomavirus type 16 and immune status in human immunodeficiency virus-
seropositive women. J Natl Cancer Inst. 2003;95(14):1062-71. 
78. Abraham AG, D'Souza G, Jing Y, Gange SJ, Sterling TR, Silverberg MJ, et al. 
Invasive cervical cancer risk among HIV-infected women: a North American multicohort 
collaboration prospective study. J Acquir Immune Defic Syndr. 2013;62(4):405-13. 
79. Serraino D, Carrieri P, Pradier C, Bidoli E, Dorrucci M, Ghetti E, et al. Risk of 
invasive cervical cancer among women with, or at risk for, HIV infection. Int J Cancer. 
1999;82(3):334-7. 
80. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in 
patients with human immunodeficiency virus infection and acquired immunodeficiency 
syndrome. J Natl Cancer Inst. 2000;92(18):1500-10. 
81. Wheeler CM. The natural history of cervical human papillomavirus infections and 
cervical cancer: gaps in knowledge and future horizons. Obstet Gynecol Clin North Am. 
2013;40(2):165-76. 
82. Harris TG, Burk RD, Xue X, Anastos K, Minkoff H, Massad LS, et al. 
Association of cutaneous anergy with human papillomavirus and cervical neoplasia in 
HIV-seropositive and seronegative women. Aids. 2007;21(14):1933-41. 
83. Howard TP, Solomon DA. Reading the tuberculin skin test. Who, when, and 
how? Arch Intern Med. 1988;148(11):2457-9. 
84. Anergy skin testing and tuberculosis [corrected] preventive therapy for HIV-
infected persons: revised recommendations. Centers for Disease Control and Prevention. 
MMWR Recomm Rep. 1997;46(RR-15):1-10. 
85. Wright PW, Crutcher JE, Holiday DB. Selection of skin test antigens to evaluate 
PPD anergy. J Fam Pract. 1995;41(1):59-64. 
86. CDC. Mantoux Tuberculin Skin Test Videotape Facilitator Guide  [cited 2009 
3/30/09]. Available from: http://www.cdc.gov/tb/pubs/Mantoux/guide.htm. 
87. Rosenstreich DL. Evaluation of delayed hypersensitivity: from PPD to poison ivy. 
Allergy Proc. 1993;14(6):395-400. 
88. Nowak RG, Gravitt PE, Morrison CS, Gange SJ, Kwok C, Oliver AE, et al. 
Increases in human papillomavirus detection during early HIV infection among women 
in Zimbabwe. J Infect Dis. 2011;203(8):1182-91. 
89. Wang C, Wright TC, Denny L, Kuhn L. Rapid rise in detection of human 
papillomavirus (HPV) infection soon after incident HIV infection among South African 
women. J Infect Dis. 2011;203(4):479-86. 
 29 
90. Plummer M, Herrero R, Franceschi S, Meijer CJ, Snijders P, Bosch FX, et al. 
Smoking and cervical cancer: pooled analysis of the IARC multi-centric case--control 
study. Cancer causes & control : CCC. 2003;14(9):805-14. 
91. Moreno V, Bosch FX, Munoz N, Meijer CJ, Shah KV, Walboomers JM, et al. 
Effect of oral contraceptives on risk of cervical cancer in women with human 
papillomavirus infection: the IARC multicentric case-control study. Lancet. 
2002;359(9312):1085-92. 
92. Vaccarella S, Herrero R, Dai M, Snijders PJ, Meijer CJ, Thomas JO, et al. 
Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled 
analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev. 
2006;15(11):2148-53. 
93. Marks M, Gravitt PE, Gupta SB, Liaw KL, Tadesse A, Kim E, et al. Combined 
oral contraceptive use increases HPV persistence but not new HPV detection in a cohort 
of women from Thailand. J Infect Dis. 2011;204(10):1505-13. 
94. Castellsague X, Munoz N. Chapter 3: Cofactors in human papillomavirus 
carcinogenesis--role of parity, oral contraceptives, and tobacco smoking. Journal of the 
National Cancer Institute Monographs. 2003(31):20-8. 
95. Munoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, et al. Role of 
parity and human papillomavirus in cervical cancer: the IARC multicentric case-control 
study. Lancet. 2002;359(9312):1093-101. 
96. Minkoff H, Feldman JG, Strickler HD, Watts DH, Bacon MC, Levine A, et al. 
Relationship between smoking and human papillomavirus infections in HIV-infected and 
-uninfected women. J Infect Dis. 2004;189(10):1821-8. 
97. McIntyre-Seltman K, Castle PE, Guido R, Schiffman M, Wheeler CM, Group A. 
Smoking is a risk factor for cervical intraepithelial neoplasia grade 3 among oncogenic 
human papillomavirus DNA-positive women with equivocal or mildly abnormal 
cytology. Cancer Epidemiol Biomarkers Prev. 2005;14(5):1165-70. 
98. Koshiol J, Schroeder J, Jamieson DJ, Marshall SW, Duerr A, Heilig CM, et al. 
Smoking and time to clearance of human papillomavirus infection in HIV-seropositive 
and HIV-seronegative women. Am J Epidemiol. 2006;164(2):176-83. 
99. Poppe WA, Ide PS, Drijkoningen MP, Lauweryns JM, Van Assche FA. Tobacco 
smoking impairs the local immunosurveillance in the uterine cervix. An 
immunohistochemical study. Gynecologic and obstetric investigation. 1995;39(1):34-8. 
100. Phelan DF, Gange SJ, Ahdieh-Grant L, Mehta SH, Kirk GD, Shah K, et al. 
Determinants of Newly Detected Human Papillomavirus Infection in HIV-Infected and 
HIV-Uninfected Injection Drug Using Women. Sex Transm Dis. 2009. 
101. Minkoff H, Zhong Y, Strickler HD, Watts DH, Palefsky JM, Levine AM, et al. 
The relationship between cocaine use and human papillomavirus infections in HIV-
seropositive and HIV-seronegative women. Infect Dis Obstet Gynecol. 
2008;2008:587082. 
102. Serraino D, Napoli PA, Zaccarelli M, Alliegro MB, Pezzotti P, Rezza G. High 
frequency of invasive cervical cancer among female injecting drug users with AIDS in 
Italy. Aids. 1996;10(9):1041-2. 
103. Syrjanen K, Naud P, Derchain S, Roteli-Martins C, Longatto-Filho A, Tatti S, et 
al. Drug addiction is not an independent risk factor for oncogenic human papillomavirus 
 30 
infections or high-grade cervical intraepithelial neoplasia: case-control study nested 
within the Latin American Screening study cohort. Int J STD AIDS. 2008;19(4):251-8. 
104. Reece A. Lifetime prevalence of cervical neoplasia in addicted and medical 
patients. The Australian & New Zealand journal of obstetrics & gynaecology. 
2007;47(5):419-23. 
105. Kricker A, Burns L, Goumas C, Armstrong BK. Cervical screening, high-grade 
squamous lesions, and cervical cancer in illicit drug users. Cancer causes & control : 
CCC. 2013;24(7):1449-57. 
106. Temmerman M, Tyndall MW, Kidula N, Claeys P, Muchiri L, Quint W. Risk 
factors for human papillomavirus and cervical precancerous lesions, and the role of 
concurrent HIV-1 infection. International journal of gynaecology and obstetrics: the 
official organ of the International Federation of Gynaecology and Obstetrics. 
1999;65(2):171-81. 
107. Celentano DD, Latimore AD, Mehta SH. Variations in sexual risks in drug users: 
emerging themes in a behavioral context. Curr HIV/AIDS Rep. 2008;5(4):212-8. 
108. Vlahov D, Safaien M, Lai S, Strathdee SA, Johnson L, Sterling T, et al. Sexual 
and drug risk-related behaviours after initiating highly active antiretroviral therapy 
among injection drug users. Aids. 2001;15(17):2311-6. 
109. Baldwin GC, Roth MD, Tashkin DP. Acute and chronic effects of cocaine on the 
immune system and the possible link to AIDS. J Neuroimmunol. 1998;83(1-2):133-8. 
110. Cabral GA. Drugs of abuse, immune modulation, and AIDS. J Neuroimmune 
Pharmacol. 2006;1(3):280-95. 
111. Agarossi A, Casolati E, Valieri M, Ferrazzi E, Maffeis G, Trabattoni D, et al. 
Mucosal immune response to Human Papilloma Virus (HPV) infection in HIV positive 
women. Med Wieku Rozwoj. 2003;7(4 Pt 1):495-502. 
112. Friedman H, Newton C, Klein TW. Microbial infections, immunomodulation, and 
drugs of abuse. Clinical microbiology reviews. 2003;16(2):209-19. 
113. Lopez MC, Watson RR. Effect of cocaine and murine AIDS on lamina propria T 
and B cells in normal mice. Life Sci. 1994;54(9):PL147-51. 
114. Watson ES, Murphy JC, ElSohly HN, ElSohly MA, Turner CE. Effects of the 
administration of coca alkaloids on the primary immune responses of mice: interaction 
with delta 9-tetrahydrocannabinol and ethanol. Toxicol Appl Pharmacol. 1983;71(1):1-
13. 
115. Starec M, Rouveix B, Sinet M, Chau F, Desforges B, Pocidalo JJ, et al. Immune 
status and survival of opiate- and cocaine-treated mice infected with Friend virus. J 
Pharmacol Exp Ther. 1991;259(2):745-50. 
116. Friedman H, Pross S, Klein TW. Addictive drugs and their relationship with 
infectious diseases. FEMS Immunol Med Microbiol. 2006;47(3):330-42. 
117. Cook JA, Burke-Miller JK, Cohen MH, Cook RL, Vlahov D, Wilson TE, et al. 
Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 





Cocaine use and immune suppression in HIV-infected and at-risk uninfected women 





Background: Cocaine use has been linked to an increased risk of prevalent and incident 
HPV infection. Cocaine has also shown to exert immune suppressive effects in 
laboratory and animal settings. However, cocaine has not yet been examined in 
populations at high risk for human papillomavirus (HPV) infection and reactivation. The 
potential influence of cocaine on the role of host immune control and subsequent viral 
clearance and suppression of viral replication is critical to understanding the natural 
history of HPV infection.  
Objective: To evaluate the association between cocaine use and epithelial immune 
suppression, measured by cutaneous anergy, in a population of HIV-infected and at-risk 
HIV-uninfected female participants in a HIV natural history study.  
Methods: We conducted a cross-sectional analysis of 1,373 women enrolled in a 
prospective cohort study at six U.S. sites with an anergy test completed in the pre-
HAART era (before July 1996). We used logistic regression to model the association 
between recent use of cocaine and cutaneous anergy, adjusting for age, sexual risk 
behavior, use of other illicit drugs, employment status, and body mass index, and 
stratified our results by HIV serostatus. 
Results: Overall, 46% (n=635) of women were found to have a diminished immune 
response indicating anergy. Among HIV-uninfected women, those who reported recent 
cocaine use had more than double the risk of having an anergic test result compared to 
non-cocaine-users (OR 2.29, 95% C.I.: 1.06-4.95). However, no association was 
observed among HIV-infected women. 
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Conclusion: Recent use of cocaine was found to be associated with decreased epithelial 
immunity among women without HIV infection, which has important implications for 
understanding HPV natural history. Moreover, the risk of having an anergic test result 
was magnified after accounting for sexual risk behaviors, lending support to the 
hypothesis that immune suppression resulting from cocaine use may in part explain the 





Human papillomavirus (HPV) infection is the most common sexually transmitted 
infection, with an estimated annual incidence of 14 million among persons aged 15 to 44 
years in the United States (1). At any given time, HPV infection affects over one-quarter 
of women of reproductive age (2) and the cumulative prevalence of HPV among 
adolescent women can be as high as 81% (3). While a minority of high-risk HPV 
infections can progress to invasive cervical cancer, the vast majority of infections appear 
to result in a robust immune response leading to loss of HPV DNA detection with 1-2 
years of infection (4, 5). While previous convention was that loss of HPV DNA 
detection indicated complete virologic clearance, increasing evidence suggests that it 
actually may reflect robust immunologic control of very low copy HPV DNA 
persistence (or latency) in the basal epithelial cells (6, 7). In light of this new model of 
HPV natural history, risk factors associated with new HPV detection should be 
evaluated as potentially increasing both risk of HPV acquisition and/or loss of 
immunological control of latent HPV.   
We have previously reported an increased occurrence of prevalent and incident 
HPV infection among women using cocaine and/or crack cocaine, independent of sexual 
risk behaviors, in a long-standing cohort of HIV-infected and uninfected women 
(Women’s Interagency HIV Study [WIHS]) as well as a cohort of HIV-infected and 
uninfected women with a history of injecting drug use (AIDS Linked to the IntraVenous 
Experience [ALIVE]) (8, 9).  The specificity of the association with cocaine/crack use 
and the absence of significant attenuation of risk after sexual behavior adjustment 
suggest that this association may be mediated by the immune suppressive effects of 
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cocaine/crack use on control of latent human papillomavirus infection (8, 9). Cocaine is 
known to exert immune suppressive effects, including reduction in delayed-type 
hypersensitivity responses and reduced effector cell proliferation, in animal and in vitro 
models, providing biological plausibility for this hypothesis (10-13). 
Direct assessment of memory T-cell responses in observational cohorts would 
require HPV type-specific stimulation of tissue-resident lymphocytes, which is not 
feasible with current technology.  Therefore, in order to investigate a possible mediating 
effect of immune suppression on the association between cocaine/crack use and HPV 
detection, we evaluated the association between cocaine/crack use and the presence of 
cutaneous anergy. Cutaneous anergy testing uses common antigens (e.g., Candida 
albicans, tetanus toxoid, and mumps) to assess local T-cell-dependent immune response 
at the epithelial cell level (14), and has been associated with prevalent cervical lesions 
and incident oncogenic HPV types in a previous sample of HIV-negative and HIV-
positive women in the WIHS (14). 
 We hypothesize that cocaine use may be associated with suppression of immune 
function in epithelial tissue, thereby allowing for reactivation of a latent infection. No 
studies to date have examined the direct association between cocaine use and immune 
suppression in a U.S. population at high risk for cervical HPV infection and reactivation. 
Our objective was to assess the association between cocaine use and epithelial immune 
suppression, measured by cutaneous anergy, in a population of HIV-positive and at-risk 
HIV-negative women in the United States.  
Methods 
The Women’s Interagency HIV Study (WIHS)  
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 The WIHS is a multicenter prospective cohort study designed to characterize the 
natural history and pathogenesis of HIV infection and related conditions among a 
geographically and ethnically diverse population of women. Details of the study have 
been previously described (15, 16). Briefly, HIV-seropositive and seronegative women 
were enrolled at six sites in the United States (Bronx/Manhattan, Brooklyn, Chicago, 
Los Angeles, San Francisco, and Washington, D.C.) over two periods; original 
recruitment in 1994-1995 included 2,628 women and an additional recruitment was 
conducted in 2001-2002 when 1,144 women were enrolled. Participants were scheduled 
for one visit during each 6-month calendar period (April–September and October–
March). All participants were followed at visit windows approximately six months apart 
(plus or minus six weeks), with a median of 11.42 person-years of follow-up for the 
1994-1995 recruits and 5.05 person-years for the 2001-2002 recruits. Institutional 
review board approval was obtained from each local site, and informed consent was 
obtained for each participant. 
 At study visits, participants completed an extensive structured interview to 
collect information on past and current sexual behavior, use of recreational drugs, 
smoking, alcohol, and medications, and underwent a physical and gynecologic 
examination. Blood samples were obtained in order to determine HIV serostatus, HIV 
viral RNA load and CD4 cell counts; CD4+ T cells were measured using flow cytometry 
in laboratories participating in the AIDS Clinical Trials Quality Assurance Program, and 
plasma HIV RNA levels were determined using a nucleic acid sequence-based 
amplification technique (Organon Teknika, Durham, NC) according to the 
manufacturer’s recommended protocol (17).  
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Cutaneous anergy testing was performed at baseline and every other six-month 
visit (not exceeding once per year) through March 2000 in the WIHS using the Mantoux 
technique with 0.1 cc Candida albicans antigen (Candin; Allermed Laboratories, Inc., 
San Diego, California, USA), tetanus toxoid (1:5 dilution of fluid toxoid; Connaught 
Pharmaceuticals, now Aventis Pasteur, Swiftwater, Pennsylvania, USA), and mumps 
skin test antigen (Connaught Pharmaceuticals) (14). Test administration and reading 
were standardized via individual training and by using a training video from the U.S. 
Centers for Disease Control and Prevention, per WIHS protocol. 
 
Study Population  
A total of 1,957 of 3,766 WIHS participants had at least one visit with data on 
anergy testing, of which 1,520 women had at least one visit in the pre-HAART era 
(before July 1996). Women who did not have valid anergy test results differed 
significantly from women who did by the following characteristics (p < 0.05 for all 
characteristics): they were younger, more likely to be Hispanic, more likely to be never 
married, more likely to reside at a drug treatment facility or someone else’s 
house/apartment, slightly more likely to be employed (but have similar average 
household income to those who do not have anergy results), more likely to be enrolled at 
the Los Angeles study site, less likely to have a low-grade cervical lesion, and more 
likely to be HIV-negative and have HIV viral loads less than 20,000 copies/ml and more 
likely to be on HAART. Women without valid anergy data were also less likely to have 
any STIs, more likely to never have smoked cigarettes, and were less likely to report 
injecting drugs recently, less likely to use cocaine and heroin, but more likely to use 
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other drugs (including amphetamines, narcotics, and hallucinogens). No differences 
were found between women with and without anergy data in terms of BMI, alcohol 
drinking behavior, (illicit) methadone use, and non-injection drug use, including crack 
and marijuana. After excluding 146 women with history of hysterectomy and 1 woman 
with missing drug use data, we conducted a cross-sectional analysis on existing, 
prospectively-collected data on 1,373 women to evaluate the association of drug use and 
cutaneous anergy prior to the widespread use of HAART (Figure 1) (14).  
 
Outcome Assessment 
 A participant was considered to have a valid cutaneous anergy test if the test was 
placed and read between two to three days apart and a measure for all three antigens was 
recorded (14). Anergy was coded as a dichotomous outcome: non-anergic if induration 
to any of the three antigens was ≥5 mm and anergic if indurations in response to all three 
antigens were <5 mm in diameter. This 5mm cutpoint for classifying cutaneous anergy 
test results is aligned with existing literature describing anergy testing among HIV-
positive populations (14, 18-20). Anergic skin testing results indicate a lack of epithelial 
cell-mediated immunity, or the inability to mount a normal DTH immune response to 
foreign antigen, and non-anergic skin testing results indicate intact cell-mediated 
immunity. 
 
Exposure Assessment  
 Participants’ drug use for the prior six-month time period was self-reported 
during interviews conducted by trained study personnel. Data were collected for the 
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following drug types: cocaine, crack cocaine, heroin, and marijuana, including 
frequency of use and route of administration (injection vs. non-injection). For this 
analysis, any cocaine use includes recent exposure to cocaine or crack cocaine by any 
route, and will be referred to simply as cocaine use. 
 
Covariates 
 Age was collected as a continuous variable and re-centered around the mean 
(35.8 years) for inclusion in multivariate models. Race/ethnicity was categorized as 
Black, Hispanic, White, and Other. Employment status was dichotomized into currently 
employed and not currently employed. Highest level of education achieved was 
categorized as none (no schooling), primary only, some high school, completed high 
school, some college, completed four years of college, and attended/completed graduate 
school.  Study site was categorized by city or region as Bronx, Brooklyn, Chicago, and 
District of Columbia/Maryland/Virginia. Measures of sexual risk behaviors included 
lifetime number of male sexual partners (0-4 partners, 5-9 partners, 10-49 partners, and 
≥ 50 partners), number of male sexual partners since last study visit (0, 1, 2, and ≥3 
partners), and recent report of sexually transmitted infection (categorized as none or any 
STIs reported in the previous six months). Data on HIV serostatus (positive, negative), 
HIV-related immune markers, e.g., CD4+ cell count (>500 cells/mm3, 200-500 
cells/mm3, <200 cells/mm3), HIV RNA level (<4,000 copies/ml, 4,000-20,000 
copies/ml, 20,000-100,000 copies/ml, ≥100,000 copies/ml), current pregnancy status 
(pregnant, not pregnant), recent alcohol use (abstainer, light [<3 drinks/week], moderate 
[3-13 drinks/week], heavy [≥14 drinks/week]), and current smoking status (no, yes) 
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were also categorized for inclusion in analyses. Body mass index (BMI) was categorized 
according to standardized national and international guidelines(21) for determining 
weight status for adults 20 years of age and older: underweight (<18.5), normal weight 
(18.5-24.9), overweight (25-29.9), and obese (≥30).  
 
Statistical Analysis 
 Demographic, immunologic, virologic, and behavioral characteristics at the time 
of anergy measurement were compared across persons who reported any cocaine use 
compared to those who reported no cocaine use using chi-square and Fisher’s exact 
tests, when necessary. We selected covariates based on a priori knowledge and 
statistically significant associations with exposure and outcome in univariate logistic 
regression analyses (p<0.10). We used a series of logistic regression models to estimate 
the association between recent use of drugs (any cocaine, any heroin, and any cocaine or 
heroin in separate models) and anergy adjusting for the following covariates: lifetime 
and recent number of male sexual partners, use of other drugs (e.g., marijuana and 
heroin for models with any cocaine exposure, marijuana for models using any cocaine or 
heroin exposure, cocaine and marijuana for models with any heroin exposure), and BMI. 
We also stratified on HIV status to examine the potential direct immunological effect of 
drug use independent of HIV-induced immune suppression. 
All statistical tests were two-sided, and a p-value of less than 0.05 was 
considered statistically significant. All statistical analyses were conducted using STATA 






Demographic characteristics of the study population reflect the overall WIHS 
cohort from which they were selected(16): 772 (56.2%) were Black, 326 (23.7%) were 
Hispanic and 236 (17.2%) were White. Median age of women included in the analysis 
was 35.8 years, with a range of 17-66 years of age (16). 
Overall, 286 women (21%) reported recent use (prior six months) of any cocaine 
or crack cocaine (Table 1). Thirteen percent of the 1,373 women reported recent cocaine 
use, 15% reported crack use and 11% reported heroin use.  Among those who reported 
any cocaine use, nearly three-quarters reported crack use and 40% reported heroin use. 
Most women (75%) who reported recent heroin use also used cocaine. 
Persons who reported recent cocaine (including crack) use were more likely than 
those who did not to be older (over 40 years old), Black, unemployed, and have less than 
a high school education (Table 1). Cocaine users were more likely to be normal weight 
or underweight, report exchanging sex for money, drugs, or shelter, and report two or 
more recent male sexual partners and more than fifty lifetime male sexual partners. 
Women who reported recent cocaine use were more likely to be HIV-negative, have 
CD4 cell counts greater than 500 cells/mm3, have lower HIV viral load, and not be on 
any HIV treatment. Distributions of abnormal Pap smear, cervical treatment since last 
visit, multiple STIs and pregnancy status did not differ between persons who reported 





 A total of 635 women (46%) had a diminished DTH response indicating anergy 
(Table 2). There was no association between cocaine use and anergy in the overall 
analytic cohort (OR=1.03, 95% C.I.: 0.79-1.34), nor was there any association between 
use of any individual drugs (e.g., OR for heroin = 0.99, 95% C.I.: 0.71-1.39); OR for 
marijuana = 0.82, 95% C.I.: 0.61-1.05), OR for crack = 1.08, 95% C.I.: 0.80-1.45), OR 
for cocaine = 0.84, 95% C.I.: 0.61-1.16) and anergy, or drug administration types (e.g., 
OR for injection drugs = 0.95, 95% C.I.: 0.65-1.40; OR for non-injection drugs = 0.90, 
95% C.I.: 0.72-1.13) and anergy. However, anergy (i.e., diminished DTH responses 
under 5mm induration) was associated with being older, study site, and being 
unemployed. Anergic responses were more likely to be observed among women with no 
recent male sex partners, normal weight, abnormal Pap result, and recently detected 
oncogenic HPV type. Women with anergy were more likely to be HIV positive and have 
higher HIV viral load and peripheral CD4+ T-cell counts under 200 cells/mm3. 
 
Stratified by HIV serostatus 
In order to isolate the effect of cocaine use and immune response not influenced 
by HIV-associated immune suppression, we conducted stratified analysis by HIV 
serostatus. In unadjusted analysis among HIV uninfected women, we observed a 
statistically significant, increased odds of anergy associated with recent cocaine use (OR 
= 1.89, 95% C.I.: 1.05-3.40 (Table 3, Model 1). Adjusting for use of other drugs (e.g., 
marijuana and heroin) increased the magnitude of the effect estimate by approximately 
five percent (OR = 1.99, 95% C.I.: 1.03-3.83) (Table 3, Model 2). Adjusting for other 
potential confounders including age, employment status, recent number of male sex 
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partners, lifetime number of male sex partners, study site, BMI, and other drug use 
(marijuana and heroin), the association between recent cocaine use and anergy 
strengthened in magnitude and remained statistically significant (OR=2.29 (95% C.I.: 
1.06-4.95) (Table 3, Model 3). 
In unadjusted analysis among HIV uninfected women, we also observed 
statistically significant, increased odds of anergy among HIV-negative women 
associated with recent heroin use (OR=2.15; 95% C.I.: 1.06-4.36) (Table 3, Model 1). 
After adjustment for the aforementioned covariates including crack/cocaine, the effect 
estimate was attenuated (OR=1.73, 95% C.I.: 0.74-4.04), and results were not 
statistically significant (Table 3, Model 3).  
Among HIV-positive women, there was no evidence for any association between 




 Evidence supporting the biological effect of cocaine use on immune suppression 
was observed in this study among HIV-uninfected women. There was a greater than 
two-fold, statistically significant risk of diminished DTH response (indicating anergy) 
associated with recent cocaine use (including crack) among HIV-uninfected women. By 
contrast, we did not observe any association between cocaine use and immune 
suppression among HIV-infected women. Since HIV-infected women have profound 
HIV-mediated immune suppression, it was unlikely that we would have observed the 
association of diminished DTH response with cocaine use among participants with HIV 
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infection. We further did not observe statistically significant associations between other 
drugs (e.g., heroin) and immune suppression among HIV-infected or -uninfected 
women.  
   Among HIV-negative women, our finding that use of cocaine, and not other 
drugs such as heroin, was independently associated with increased risk of anergy is 
supported by existing laboratory and clinical data. Cocaine has broad immune 
suppressive effects in animal and in vitro models (11, 22), including decreasing pro-
inflammatory IgA+ cells, increasing the number of CD8+ cells in mucosal tissue (23), 
and inhibiting DTH response to dinitrofluorobenzene (DNFB) (24). Despite a small 
sample size, an experimental study of 30 healthy men and women demonstrated that 
cocaine induced suppression of IL-6, a pro-inflammatory cytokine important for 
mediating host response to infection (25). In contrast to cocaine’s direct 
immunomodulatory effects in vivo (12), heroin-associated effects on the immune system 
are considered indirect and complex, involving interaction with the hypothalamus-
pituitary-adrenal (HPA) axis and central nervous system (26, 27). Not surprisingly, we 
failed to observe independent associations of immune suppression with any other drugs. 
These differential effects of cocaine and heroin on immune cell function provides further 
biological support for the association we observed among HIV-uninfected women which 
appears to be specific to cocaine use rather than global drug use.  
 Further demonstrating the specific association between cocaine and immune 
suppression, there was a two-fold risk of anergy with heroin use in an unadjusted model, 
but after accounting for cocaine use, the estimate was attenuated and lost statistical 
significance (Table 3, Model 3, Heroin). Based on the independent associations 
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observed with cocaine and that the majority of heroin users in this study also reported 
using cocaine, it is possible that the association between any cocaine or heroin and 
anergy may be largely driven by cocaine use (Table 3, Model 3, Any cocaine or heroin).  
 In addition, epidemiologic evidence from this cohort (9) and a similar HIV-
positive and at-risk HIV-negative U.S. cohort (8) shows similar specificity of 
association between cocaine use and HPV infection. We observed an increase in effect 
size after accounting for sexual risk behaviors in this study, which may suggest that a 
cocaine-HPV association may be mediated by the immune suppressive effects of 
cocaine use on control of latent (undetectable) HPV infection, further lending support 
for a direct biological cause and potentially lesser influence of sexual risk on new HPV 
detection.  
This study has several potential limitations. We did not have sufficient power to 
examine the effect of route of administration of drug use, frequency of use, nor 
cumulative drug use. However, we used existing data from a nationally-representative 
sample of at-risk, HIV-uninfected women in the United States and were able to identify 
an independent cocaine association with cutaneous anergy. In addition to limited 
statistical power, there are inherent difficulties in the clinical measure used to test for 
anergy. First, skin testing results are dependent on recall antigens. If an individual had 
not been exposed to the antigen prior to the placement of recall antigen, there would be 
no visible induration mounted in response to a novel antigen, thus appearing anergic 
without truly having reduced cell-mediated immunity. Nevertheless, if this occurred, we 
would expect this non-differential misclassification to bias our results towards the null. 
Secondly, exposure to common antigens may vary geographically (18); however, it is 
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accepted that the three antigens used in this study are equally distributed throughout the 
United States (28). To safeguard against bias from differential antigen exposures across 
study sites, we included a covariate for study site in multivariate models to account for 
potential antigenic variation as well as potential variability in drug formulation and 
potency across sites. Other investigators have suggested that anergy may be best 
classified using simply two antigens: mumps and tetanus (18). However, anergy testing 
has been typically and historically defined in the clinic and in other epidemiologic 
studies as any induration observed to the three antigens we used in our analysis: tetanus, 
mumps, and Candida antigens (14, 28, 29). Sensitivity analyses using a two antigen 
definition (mumps and tetanus) did not yield results that differed substantially from what 
we report here.  
A recent review of HPV clinical immunology (30) highlighted that immune 
evasion by HPV uses strategies of downregulation of the innate immune system via 
Langerhans’ cells, dendritic cells, and toll-like receptors (TLRs), and of the cell-
mediated immune system’s T cells and neutralizing antibodies. We acknowledge that 
other immune markers, such as diminished plasmacytoid dendritic cell (PDC) counts, 
which have been found to be predictive of infections among HIV-infected women (30),  
or gamma interferon and interleukin-2 cytokines, which have been described as optimal 
in vitro correlates of DTH (31), may be more direct measures of drug-induced immune 
suppression. Markers such as these may be important for control of HPV infection and 
reactivation, and may be explored in future studies as potential indicators of drug-
associated immune compromise. However, anergy skin testing is an easily administered 
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and well-tolerated method to measure cell-mediated immunity at the cutaneous surface 
(31).  
 Despite these potential limitations, there were several strengths to this study. 
Using a nationally representative sample of women who are at risk for HIV infection 
and opportunistic infections, we were able to account for use of other drugs including 
heroin and marijuana in the same time period as our main exposure of interest, cocaine. 
Polysubstance abuse is common among drug-using populations (32), and it is critical to 
consider the potential combined effects, whether antagonistic or synergistic, of multiple 
drug use. By creating exposure variables based on the chemical compound(s) used, 
regardless of route of administration, we were able to identify striking effects with 
exposure to any cocaine formulation (crack cocaine or cocaine), while effects of heroin 
exposure on this type of immunologic response were not supported by the data. To our 
knowledge, this study is the first to examine the direct effect of cocaine use on 
cutaneous anergy in the context of immune suppression and HPV infection in high-risk, 
drug-using women.  
 In summary, cocaine use was associated with a marker of epithelial immune 
suppression, and supports the hypothesis that the association of cocaine with new HPV 
detection might be explained by loss of immunologic control, as well as new acquisition. 
Anergy skin testing serves as a simple clinical measure of lack of immune response at 
the epithelial cell level, which may be analogous to the immune microenvironment 
responsible for suppressing active HPV replication at the cervix, further supporting the 
hypothesis that cocaine-using women are susceptible to reactivation of latent HPV 
infection. These findings call attention to careful evaluation of risk factors for new HPV 
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detection in the context of risk of loss of immunologic control of undetectable persistent 
(latent) infections, as well as risk of acquisition. As the burden of drug use among 
women has increased since 2000 (33), it is crucial to understand potential implications 
of drug use on immunologic states favoring HPV proliferation in these high-risk and 
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Table 1. Demographic, clinical, and behavioral characteristics by any recent cocaine use 
(including crack cocaine) reported at cutaneous anergy test visit, Women’s Interagency 


















       
Total 1087 79.2 286 20.8 1373  
       
Demographics       
       
Age (years)       
<25 92 8.5 6 2.1 98 <.0005 
25-29 181 16.7 41 14.3 222  
30-34  260 23.9 65 22.7 325  
35-39  294 27.1 81 28.3 375  
40-44  1557 14.4 63 22.0 220  
≥45  103 9.5 30 10.5 133  
       
Race       
Black 582 53.5 190 66.4 772 0.001 
Hispanic 275 25.3 51 17.8 326  
Other 36 3.3 3 1.1 39  
White 194 17.9 42 14.7 236  
       
Study site       
Bronx 282 25.9 103 36.0 385 <.0005 
Brooklyn 241 22.2 42 14.7 283  
Chicago 151 13.9 47 16.4 198  
DC/MD/VA 169 15.6 22 7.7 191  
LA 141 13.0 22 7.7 163  
SF 103 9.5 50 17.5 153  
       
Employment status       
Not employed 759 69.8 258 90.2 1017 <.0005 
Employed 325 29.9 28 9.8 353  
       
Highest level of       
education achieved      
Less than high school 367 33.8 128 44.8 495 0.001 
Completed high school  720 66.2 158 55.2 878  


















Substance Use       
       
Cocaine use       
No 1087 100 110 38.5 1197 <.0005 
Yes 0 0 176 61.5 176  
       
Crack cocaine use       
No 1087 100 75 26.2 1162 <.0005 
Yes 0 0 211 73.8 211  
       
Heroin use       
No 1048 96.4 171 59.8 1219 <.0005 
Yes 39 3.6 115 40.2 154  
       
Marijuana use       
No 892 82.2 139 48.6 1031 <.0005 
Yes 193 17.8 147 51.4 340  
       
Injection drug use       
No 1062 97.7 198 69.2 1260 <.0005 
Yes 25 2.3 88 30.8 113  
       
Non-injection drug use       
No 887 81.6 32 11.2 919 <.0005 
Yes 200 18.4 254 88.8 454  
       
Current cigarette smoking      
No 563 51.8 33 11.5 596 <.0005 
Yes 524 48.2 253 88.5 777  
       
Alcohol use (drinks/week)      
Abstainer 541 49.8 63 22.0 604 <.0005 
Light (<3) 343 31.6 75 26.2 418  
Moderate (3-13) 138 12.7 73 25.5 211  
Heavy (≥14) 42 3.9 71 24.8 113  
       
Sexual Risk Behavior       
       
Exchanged sex for money, drugs, or shelter     
No 735 67.6 118 41.3 853 <.0005 
Yes 348 32.0 167 58.4 515  

















       
Male sex partners       
None 337 31.0 69 24.1 406 <.0005 
1 621 57.1 119 41.6 740  
2 88 8.1 41 14.3 129  
3 or more 39 3.6 55 19.2 94  
       
Lifetime male sex partners      
0-4 206 19.0 28 9.8 234 <.0005 
5-9  246 22.6 43 15.0 289  
10-49 357 32.8 88 30.8 445  
≥50 244 22.5 114 39.9 358  
       
HIV-Related Characteristics      
       
HIV serostatus       
Converter identified at 
death 4 0.4 5 1.8 9 <.0005 
Negative 197 18.1 75 26.2 272  
Prevalent (positive) 886 81.5 206 72.0 1092  
       
HIV viral load 
(copies/ml)       
< 4,000 113 10.4 37 12.9 150 0.001 
4,000-20,000 350 32.2 74 25.9 424  
20,000-100,000 191 17.6 55 19.2 246  
>100,000 209 19.2 36 12.6 245  
       
CD4 cell count 
(cells/mm3)       
> 500 398 36.6 130 45.5% 528 0.004 
200-500 398 36.6 98 34.3% 496  
< 200 262 24.1 46 16.1% 308  
       
Clinical Characteristics      
       
Body mass index (BMI; kg/m2)       
Underweight, <18.5 30 2.8 18 6.5 48 <.0005 
Normal weight, 18.5-
24.9 405 37.9 151 54.1 556  
Overweight, 25-29.9 320 29.9 73 26.2 393  

















       
Anergy skin test result       
Non-anergic 586 53.9 152 53.1 738 0.82 
Anergic  501 46.1 134 46.9 635  
       
Abnormal Pap result       
No 909 83.6 229 80.1 1138 0.28 
Yes 139 12.8 47 16.4 186  
       
HPV type(s) detected       
Non-oncogenic HPV 308 28.3 72 25.2 380 0.003 
Any Oncogenic HPV 273 25.1 81 28.3 354  
No HPV (Negative) 459 42.2 106 37.1 565  
       
Current pregnancy 
status       
No 1062 97.7 279 97.6 1341 0.46 
Yes 17 1.6 3 1.1 20  
*p-values reported are based on chi-squared or Fisher’s exact tests 
 
Column percentages may not sum to 100% due to rounding and/or missing values. 
 
Characteristics refer to the prior six month period unless otherwise noted. 
 
Abbreviations: STI, sexually transmitted infection; HIV, human immunodeficiency 




Table 2. Demographic, clinical, and behavioral characteristics reported at cutaneous 










       
Total 738 53.7 635 46.3 1373  
       
Demographics       
       
Age (years)       
<25 61 8.3 37 5.8 98 0.02 
25-29 136 18.4 86 13.5 222  
30-34  179 24.3 146 23.0 325  
35-39  184 24.9 191 30.1 375  
40-44  111 15.0 109 17.2 220  
≥45  67 9.1 66 10.4 133  
       
Race       
Black 429 58.1 343 54.0 772 0.42 
Hispanic 170 23.0 156 24.6 326  
Other 18 2.4 21 3.3 39  
White 121 16.4 115 18.1 236  
       
Study site       
Bronx 194 26.3 191 30.1 385 <0.0005 
Brooklyn 180 24.4 103 16.2 283  
Chicago 119 16.1 79 12.4 198  
DC/MD/VA 98 13.3 93 14.7 191  
LA 68 9.2 95 15.0 163  
SF 79 10.7 74 11.7 153  
       
Employment status       
Not employed 522 70.7 495 78.0 1017 0.006 
Employed 215 29.1 138 21.7 353  
       
Highest level of 
education achieved       
Less than high school 272 36.9 223 35.1 495 0.50 
Completed high 
school 466 63.1 412 64.9 878  














       
Substance Use       
       
Cocaine, crack 
cocaine, or heroin       
No 565 76.6 483 76.1 1048 0.83 
Yes 173 23.4 152 23.9 325  
       
Any cocaine 
(including crack)       
No 586 79.4 501 78.9 1087 0.82 
Yes 152 20.6 134 21.1 286  
       
Any heroin       
No 655 88.7 564 88.8 1219 0.97 
Yes 83 11.3 71 11.2 154  
       
Crack cocaine       
No 628 85.1 534 84.1 1162 0.61 
Yes 110 14.9 101 15.9 211  
       
Marijuana       
No 541 73.3 490 77.2 1031 0.12 
Yes 195 26.4 145 22.8 340  
       
Injection drug       
No 676 91.6 584 92.0 1260 0.81 
Yes 62 8.4 51 8.0 113  
       
Non-injection drug       
No 486 65.9 433 68.2 919 0.36 
Yes 252 34.1 202 31.8 454  
       
Current cigarette 
smoking       
No 322 43.6 274 43.2 596 0.86 
Yes 416 56.4 361 56.9 777  
       
Alcohol Use (drinks/week)      
Abstainer 316 42.8 288 45.4 604 0.65 
Light (<3) 227 30.8 191 30.1 418  
Moderate (3-13) 120 16.3 91 14.3 211  













       
Sexual Risk Behavior       
       
Exchanged sex for 
money, drugs, or 
shelter       
No 454 61.5 399 62.8 853 0.71 
Yes 282 38.2 233 36.7 515  
       
Male sex partners        
None 190 25.8 216 34.0 406 0.007 
1 412 55.8 328 51.7 740  
2  81 11.0 48 7.6 129  
3 or more 52 7.1 42 6.6 94  
       
Lifetime number of 
male sexual partners       
0-4 114 15.4 120 18.9 234 0.45 
5-9 159 21.5 130 20.5 289  
10-49 250 33.9 195 30.7 445  
≥50  190 25.8 168 26.5 358  
       
HIV-Related 
Characteristics       
       
HIV serostatus       
Converter identified at 
death 6 0.8 3 0.5 9 <0.0005 
Negative 211 28.6 61 9.6 272  
Prevalent (positive) 521 70.6 571 89.9 1092  
       
HIV viral load 
(copies/ml)       
< 4,000 93 12.6 57 9.0 150 <0.0005 
4,000-20,000 252 34.2 172 27.1 424  
20,000-100,000 111 15.0 135 21.3 246  
>100,000 52 7.1 193 30.4 245  
       
CD4 cell count 
(cells/mm3)       
> 500 393 53.3 135 21.3 528 <0.0005 
200-500 267 36.2 229 36.1 496  













       
Clinical 
Characteristics       
       
Body mass index 
(BMI; kg/m2)        
Underweight, <18.5 26 3.5 22 3.5 48 0.07 
Normal weight, 18.5-
24.9 273 37.0 283 44.6 556  
Overweight, 25-29.9 221 30.0 172 27.1 393  
Obese, ≥30 204 27.6 147 23.2 351  
       
Abnormal Pap smear 
result       
No 659 89.3 479 75.4 1138 <0.0005 
Yes 54 7.3 132 20.8 186  
       
HPV Type(s) detected       
Non-oncogenic HPV 206 27.9 174 27.4 380 <0.0005 
Any Oncogenic HPV 140 19.0 214 33.7 354  
No HPV (Negative) 348 47.2 217 34.2 565  
       
Current pregnancy 
status       
No 721 97.7 620 97.6 1341 0.90 
Yes 10 1.4 10 1.6 20  
       
* p-values are based on chi-squared or Fisher’s exact tests. 
 
Note: Non-anergic defined by induration ≥5mm, anergic defined by induration >5mm. 
 
Column percentages may not sum to 100% due to rounding and/or missing values. 
 
Characteristics refer to the prior six month period unless otherwise noted. 
 
Abbreviations: STI, sexually transmitted infection; HIV, human immunodeficiency 





Table 3. Odds ratio (OR) estimates from unadjusted and adjusted logistic regression 
models of cutaneous anergy testing results, pre-HAART period 1994-1996, Women’s 
Interagency HIV Study (WIHS) (N=1,373) 
Reported drug 





OR (95% C.I.) N 
Model 2: 
Adjusted ORa 





Any cocaine (including crack) or heroin  
≥5mm 
induration 
738 Ref 736 Ref 696 Ref 
<5mm 
induration 
635 1.03  
(0.80-1.32) 
635 1.12  
(0.86-1.45) 
602 0.99  
(0.73-1.33) 
       
Any cocaine (including crack) 
≥5mm 
induration 
738 Ref 737 Ref 697 Ref 
<5mm 
induration 
635 1.03  
(0.80-1.34) 
635 1.19  
(0.88-1.59) 
602 1.08  
(0.78-1.50) 
       
Heroin       
≥5mm 
induration 
738 Ref 736 Ref 696 Ref 
<5mm 
induration 






       
HIV-negative women 
Any cocaine (including crack) or heroin 
≥5mm 
induration 
217 Ref 217 Ref 205 Ref 
<5mm 
induration 
64 2.16  
(1.22-3.82)c 
64 2.52  
(1.37-4.65)d 
63 2.85  
(1.35-6.04) c 
       
Any cocaine (including crack) 
≥5mm 
induration 
217 Ref 217 Ref 205 Ref 
<5mm 
induration 
64 1.89  
(1.05-3.40)e 
64 1.99  
(1.03-3.83)e 
63 2.29  
(1.06-4.95)e 
       
Heroin       
≥5mm 
induration 
217 Ref 217 Ref 205 Ref 
<5mm 
induration 
64 2.15  
(1.06-4.36)e 
64 2.03  
(0.97-4.28) 
63 1.73  
(0.74-4.04) 
a Model 2: Adjusted for other drug use only (e.g., adjusted for any recent marijuana use 
only for cocaine/crack/heroin exposure; adjusted for recent marijuana and/or heroin use 
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for cocaine/crack exposure; adjusted for recent crack, cocaine and/or marijuana use for 
heroin exposure) 
b Model 3: Adjusted for other drug use, age (centered), employment status, recent 
number of male sex partners, lifetime number of male sex partners, study site, and body 
mass index (BMI)  
c p-value < 0.01  
d p-value < 0.005  
e p-value < 0.05  





Cocaine use and incident HPV- and non-HPV-associated cervical cytological abnormalities 
among injection drug using women in Baltimore, Maryland
62 
Abstract 
Background: Cocaine use has been observed to be associated with acquisition of HPV infection 
and prevalent cervical cancer, but few studies have focused primarily on the impact of cocaine 
use on cervical cytological abnormalities.   
Objective: We sought to evaluate the association between use of crack/cocaine and risk of 
incident cervical cytological abnormalities and to quantify the relative burden of cytological 
abnormalities among current and former injection drug-using women in Baltimore, MD. 
Methods: We conducted a longitudinal analysis of 177 HIV-infected and 89 HIV-uninfected 
female participants enrolled in a18-year prospective community-based cohort study of HIV 
natural history. The women contributed 1,864 visits where valid Pap testing results were 
available. To estimate the association between recent use of cocaine and risk of incident 
cytological abnormality, we conducted logistic regression using generalized estimating equations 
and conducted stratified analysis by HIV serostatus. 
Results: Recent crack/cocaine use was associated with a slight, non-statistically significant 
increased risk of incident cervical cytological abnormality among HIV-uninfected women (OR 
1.29, 95% C.I.: 0.65-2.57). No association was observed among HIV-infected women (OR 1.01, 
95% C.I.: 0.69-1.48).  
Conclusion: Use of crack/cocaine among HIV-uninfected female injection drug users was 
marginally associated with risk of incident cervical cytological abnormalities. Cervical 
cytological abnormalities detected by Pap smear may reflect cellular changes not associated with 
risk of HPV-associated cervical cancer. Further examination to clarify the independent 
associations of cocaine use with HPV-associated clinical outcomes will require improved 
detection and larger populations of HIV-uninfected drug-using women. 
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Introduction 
 In 2012, cocaine was the third-most commonly used illicit drug in the United States, with 
the highest rate of past year dependence or abuse (after marijuana and pain relievers) in the 
United States, translating to 1.65 million persons with cocaine dependence or abuse out of a total 
of 23.9 million persons aged 12 or older classified with illicit drug dependence or abuse (1). Rates 
of current cocaine use among women have remained relatively stable in recent years; 0.3% of 
females reported using cocaine in the past month in 2012 (1).  
 Female drug users encounter multiple risks associated with drug use, including social and 
medical health risks such as drug overdose and HIV (2). Use of illicit drugs, specifically, cocaine, 
has been linked to acquisition of HPV infection(3, 4) and prevalent invasive cervical cancer(5) in 
previous epidemiologic studies.  Previously in an urban community-based cohort of current and 
former injection drug users (IDUs), prevalent and incident cervical lesions were found to be 
associated with crack/cocaine use, but the findings were limited to a small subset of the overall 
cohort that was part of a five-year gynecological sub-study focusing on HPV risk.(3) To date, few 
studies have examined the association between cocaine use and HPV-associated clinical 
outcomes.(3, 4, 6) 
 Using over 18 years of follow-up data in this same community-based cohort of current 
and former IDUs in Baltimore, Maryland, we aimed to further explore the risk of incident 
cytological abnormalities among both HIV-infected and HIV-uninfected women who use 
crack/cocaine, and to quantify the relative burden of cervical cytological abnormalities in drug-
using populations in order to better understand the role of crack/cocaine use in the natural history 




 A total of 391 women followed in the AIDS Linked to the IntraVenous Experience 
(ALIVE) study contributed 3,995 visits with any Pap test data to this analysis. The ALIVE study 
is a prospective cohort study of male and female current and former injection drug users (IDUs) 
in Baltimore, Maryland with initial enrollment in 1988-1989, and subsequent rounds of 
recruitment in 1994-1995, 1998, 2000 and 2005-2008. Details of the study have been previously 
described.(7) In brief, 2,942 IDUs were initially recruited in 1988-1989 and followed semi-
annually. At the following enrollment periods, a total of 1,603 participants were enrolled. At 
baseline, the majority of ALIVE participants were African-American (94%) and 20% were 
female. Baseline and semiannual follow-up visits included a standardized interviewer-
administered (pre-1998) or audio computer-assisted self-interview (ACASI) (post-1998) 
questionnaire to ascertain information on demographic characteristics, drug injection and non-
injection behaviors, medical history, and sexual and drug-related risk behaviors. Additionally, all 
HIV positive participants and a random sample of HIV negatives (every fifth seropositive 
participant triggered the next enrolled seronegative participant to be invited) were invited to 
participate in the clinical immunologic follow-up including a physical examination and testing for 
immunologic markers. Women also underwent Papanicolau (Pap) smears and pelvic 
examinations, as well as cervico-vaginal lavage to collect cervical specimens at semiannual 
follow-up visits.  Pap smears were collected first, with a spatula, followed by a cytobrush (except 
in pregnancy, where a cotton swab was used). Pap smears were stained and screened by a 
qualified cytotechnologist by standard criteria for cytopathologic diagnosis. All Pap smears were 
read by an external, commercial lab (Quest Diagnostics). The institutional review board at the 
Johns Hopkins University reviewed and approved the study procedures. All study participants 
provided written informed consent before enrollment in the study.  
 Female participants without a history of cervical cancer who had at least two valid Pap 
smear results during follow-up and complete data on crack/cocaine exposure at the visit where the 
Pap smear was taken were considered eligible for inclusion in this analysis. Women whose Pap 
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result indicated cervical cancer (n=2) at the first study visit were also excluded, since having 
cancer would preclude these women from being at-risk for incident cytological abnormality. Nine 
additional women had cervical cancer over the course of follow-up; we excluded the observations 
when cervical cancer was first reported and subsequent visits for these women (n=27 visits). 
Overall, women whose visits were excluded were more likely to be more immune suppressed 
(CD4 cell counts less than 200) (p<.0001) and less likely to report recent sexual intercourse with 
an injection drug user (p=0.016). However, women who were excluded were similar to eligible 
women in terms of age, BMI, cigarette smoking, sharing injection equipment, and recent sexual 
risk behavior including sexual intercourse with an anonymous partner and number of recent male 
sexual partners. The resulting analytic cohort included 277 women who contributed a total of 
1,864 visits. The overall number of observations included per woman ranged from one to 30, with 
a median of five visits per participant. 
Statistical analysis 
 Our goal was to determine if crack/cocaine use was associated with risk of incident 
abnormal Pap results, including atypical squamous cells of undetermined significance (ASCUS), 
low-grade squamous intraepithelial lesions (LSIL), and high-grade SIL (HSIL) as classified by 
the Bethesda System(8). The outcome in this study was ASCUS or more severe cytological 
abnormality detected by Pap smear at a follow-up visit (henceforth termed the ‘index visit’, i) that 
was not detected at the immediately preceding visit (i-1) with less than seven months between the 
two consecutive visits. We employed a cut-off of seven months between consecutive visits in 
order to minimize misclassification of the outcome and time-varying covariates, as these data 
were collected at each study visit referencing the prior six month time period. Visits that were 
excluded (53%) were significantly more likely to be among women who were younger 
(p=<.0001), underweight (p<.0001), HIV-infected (p<.0001), and reported greater than two 
recent male sex partners (p=0.03), but did not differ from visits that were included by women’s 
drug use status or other measures of sexual risk. 
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 We classified a woman as ‘exposed’ at a visit if she reported recent (during the prior six 
months) use of cocaine in any form and by any route, whether cocaine was injected, snorted, 
smoked (in the form of crack cocaine), or included as part of ‘speedball’ (combination heroin and 
cocaine use). We did not differentiate by route or formulation of drug as our primary interest was 
to examine the influence of the chemical compound of cocaine on cytological abnormalities. 
Henceforth, we will refer to the exposure as ‘crack/cocaine’. 
 We analyzed frequency tables comparing index visit characteristics of women who 
reported recent crack/cocaine use to women who did not report any crack/cocaine use, using 
Pearson’s chi-square and Fisher’s exact tests to compare differences in distributions of categorical 
variables (including recent use of injection and non-injection drugs, marijuana and heroin, sharing 
needles, HIV status, race, cigarette smoking, and various indicators of sexual risk behavior such 
as trading sex for money or drugs, sex with anonymous partners, STIs, and recent numbers of 
male sex partners), and Student’s t-tests and Wilcoxon rank-sum test to compare distributions of 
continuous variables (including total times injected in the last six months and last 30 days).(Table 
1) Due to the known correlation among measures taken on the same individuals over time, we 
examined the fit of various covariance patterns using the quasi-likelihood information criterion 
(QIC) for non-likelihood based methods such as generalized estimating equations (GEE)(9) and 
selected the exchangeable (uniform) correlation structure to model the covariance among 
repeated measures within individual women in this unequally-spaced, longitudinal dataset. To 
analyze the effect of self-reported cocaine use on incident cytological abnormalities over time, we 
used logistic regression models with GEE, which accounts for the correlation within subjects’ 
repeated measures over time by modeling the covariance structure within subjects.(10)  
A subset of women (n=190) between September 1992 and September 1997 had HPV type 
detection performed on specimens obtained from cervicovaginal lavage (CVL)(methods 
described elsewhere(3)). Polymerase chain reaction (PCR) amplification of HPV genomic 
sequences using consensus primers was performed on CVL specimens to detect oncogenic and 
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non-oncogenic HPV types (including HPV 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 45, 51, 52, 53, 54, 
55, 56, 58, 59, 66, 68, 73, 82, 83, 84), with negative and beta-globin controls used to ensure 
validity of HPV test results(11). Because standard of care in the United States is to triage an 
ASCUS positive test with HR-HPV DNA testing, we conducted a sensitivity analysis on 190 
women with available concurrent visit HPV type and Pap results to examine the possible 
influence of HPV negative ASCUS positive results on our analysis. Outcomes in this logistic 
regression analysis using GEE were defined by HR-HPV positive abnormal Pap result (ASCUS, 
LSIL, or HSIL) only.  
Covariates that were found to be statistically significant at a level p<0.10 in univariate 
logistic regression models, as well as those selected based on a priori knowledge, were included 
as potential confounders in the final model, including: age (<35 years; 35-49 years; 40-45 years; 
>45 years), recent cigarette smoking (yes/no), body mass index (BMI) category (underweight 
<18.5 kg/m2; normal weight 18.5-24.9 kg/m2; overweight 25-29.9 kg/m2; obese ≥30 kg/m2) and 
self-reported history of STIs (any/none). In order to separate the independent effects of 
crack/cocaine use from the known effects of HIV-related immune suppression on incident HPV-
associated abnormal Pap results(12), we conducted stratified analysis by HIV serostatus where 
possible. Data preparation was conducted in SAS, version 9.2 (SAS Institute Inc., Cary, North 
Carolina) and longitudinal analyses were conducted in STATA, version 9.2 (StataCorp, College 
Station, Texas).  
Results 
Description of Study Population 
 The median age of the 277 women at the index visit was 39.3 years and 94% of women 
were African-American (Table 1). The majority of women were HIV-positive at the index visit 
(68%), with similar prevalence of HIV positivity among non-crack/cocaine users and 
crack/cocaine users. Women who reported using crack/cocaine at the index visit were more likely 
to be underweight (BMI < 18.5 kg/m2) and normal weight (18.5-24.9 kg/m2) compared to those 
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who did not. Sexual risk behaviors reported at the index visit differed significantly between 
women who reported recent crack/cocaine use and women who did not; crack/cocaine users were 
more likely to report recent sexual intercourse with an IDU, recent sexual intercourse with an 
anonymous partner, and greater than three male sexual partners in the previous six months 
compared to those who reported no crack/cocaine use (Table 1). Compared to women who did 
not report recent crack/cocaine use, women who did were more likely to report recent injection 
and non-injection drug use, and using heroin, marijuana, and sharing injection equipment (Table 
1). Combination injection cocaine and heroin use, i.e. ‘speedball’, was reported by almost two-
thirds (66%) of crack/cocaine users. 
Crack/cocaine use and incident cervical cytological abnormalities 
 The majority (59%) of women reported recent use of crack/cocaine at the index visit. At  
the index visit, 11% of women who did not report any crack/cocaine use and 15% of those who 
reported crack/cocaine use had Pap results that indicated any incident cervical epithelial 
abnormality (either ASCUS or low- or high- grade SIL), but the difference was not statistically-
significant (Table 1a).   
 Table 2 shows the results of longitudinal analyses examining the association between 
recent crack/cocaine and incident cervical cytological abnormality. In an unadjusted logistic 
regression model with GEE, recent crack/cocaine use was associated with a slight increased risk 
of incident cytological abnormality in the overall cohort, but the estimate was not statistically 
significant (OR 1.23, 95% C.I.: 0.93-1.63).  
 In univariate logistic regression analysis using GEE, younger age, lower BMI, self-
reported history of STIs, and cigarette smoking were found to be associated with both 
crack/cocaine exposure and incident cytological abnormality; therefore, they were included in the 
multivariate model as covariates. When added to the final multivariate models, other measures of 
sexual risk behavior, including recent number of male sexual partners and recent intercourse with 
an IDU or anonymous partner, did not substantially alter our results.  
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 After stratification by HIV serostatus, we observed a positive association between 
cocaine use and incident abnormalities among HIV-uninfected women in an unadjusted model, 
but the estimate did not achieve statistical significance (OR=1.78, 95% C.I.: 0.95-3.34). This 
association was attenuated after adjusting for age, self-reported history of STIs, cigarette 
smoking, and BMI) (OR=1.29, 95% C.I.: 0.65-2.57). No association was observed in HIV-
infected women in univariate analysis (OR=1.09, 95% CI: 0.77-1.54) or after adjustment for age, 
self-reported history of STIs, cigarette smoking, and BMI (OR=1.01, 95% C.I.: 0.69-1.48) as well 
as after additional adjustment for ART use and CD4 cell count (OR=1.03, 95% C.I.: 0.70-1.53).  
Crack/cocaine use and incident HPV-positive cervical cytological abnormalities 
 Because an HR-HPV negative/ASCUS positive test is not considered to be a marker for 
intraepithelial neoplasia (13), we conducted a sensitivity analysis among the subset of women 
who had participated in a gynecological sub-study (details described elsewhere(3)) which 
included HPV genotyping. Data on HPV status and incident Pap results were available for 625 
visits among 190 women, or about 34% of the visits included in the main analysis contributed by 
69% of the women in the main analysis. The majority of women whose Pap results indicated 
incident cytological abnormality were also HPV positive: 49 of 68 visits with any incident Pap 
abnormality indicated presence of concurrent HPV infection (72%). However, 19 of 68 incident 
cytological abnormalities (28%) were HPV negative. 
  For this sub-analysis, one hundred-ninety women had eligible visits and contributed a 
median of three visits each, with a range from one to nine visits. When re-defining the outcome as 
incident cytological abnormality with concurrent HPV positivity, women with incident HPV- 
positive cytological abnormality tended to be younger (p=.026), more likely to report a history of 
STIs (p=.045), and more likely to be normal weight (and underweight) compared to those with 
normal or HPV-negative ASCUS cytology (p=.003). There was no statistically significant 
difference in reported cigarette smoking (p=.111) between women with the outcome and those 
without the outcome.  
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 No outcomes were observed among 101 visits among non-crack/cocaine-using, HIV-
uninfected women. We observed five outcomes out of 157 visits (3.18%) among crack/cocaine-
using HIV-uninfected women. Among HIV-infected women, we observed 13/142 outcomes 
(9.15%) among non-crack/cocaine-users and 31/225 outcomes (13.78%) among crack/cocaine 
users (p=0.18). 
 Table 3 shows the results of logistic regression analyses using GEE in this subset of 190 
women. Overall, we observed an increased risk of incident HPV-positive Pap abnormality 
associated with crack/cocaine use in the unadjusted model, but this was of marginal statistical 
significance (OR=1.85, 95% C.I.: 0.93-3.66). Because there were no outcomes observed among 
non-crack/cocaine-exposed HIV-uninfected women, we were unable to estimate risk associated 
with crack/cocaine use in this subgroup. Among HIV-seropositive women, we observed a 
positive, but not statistically significant unadjusted association between recent crack/cocaine use 
and incident HPV-positive cytological abnormality (OR=1.58, 95% C.I.: 0.78-3.21). Adjustment 
for age, self-reported history of STIs, cigarette smoking, and BMI attenuated odd ratio estimates 
towards the null among the overall cohort and among HIV-infected women (OR=1.41, 95% 
C.I.:0.66-2.99), and this estimate remained consistent even with additional adjustment for ARV 
use.  
Discussion 
 This study of former and current drug-using women in Baltimore found only marginal 
evidence for an association between recent cocaine use and incident cervical cytological 
abnormalities among HIV-infected and –uninfected women. We observed a non-statistically 
significant odds ratio of 1.78 among HIV-negative women; however, this estimate was 
diminished substantially after adjustment for multiple potential confounders. Among HIV-
positive women in our study, there was no evidence of an association between recent cocaine use 
and incident Pap abnormalities.  
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Our results are in contrast to a previous study using a small subgroup of this cohort(3) 
where the investigators identified recent crack use to be associated with a statistically-significant, 
1.7-fold increased odds of newly detected HPV infection among both HIV-positive and –negative 
women. In our study, drawing from the same cohort with more women and longer follow-up 
time, we observed risk estimates for incident HPV-positive cytological abnormalities among 
HIV-negative women in the same positive direction, but no increased risk was associated with 
cocaine exposure among HIV-positive women (ORadjusted=1.01). Similarly to previous findings in 
this cohort(3), Minkoff et al reported a non-statistically significant, positive association between 
crack/cocaine use in the previous six months and risk of incident HPV-positive cervical lesions 
(OR=1.51, 95% C.I.: 0.99-2.30) among women with similar HIV-associated risk factors 
throughout the U.S.(4). However, the outcome in our study included minimally abnormal 
cytological changes in addition to the cervical lesions used as the outcome in the previous studies, 
and may reflect something other than HPV-associated cytological changes. 
 One possible explanation for our inability to replicate the prior findings reported by other 
investigators is that there is no true association between cocaine and incident cytological 
abnormalities and the prior findings were spurious. A second possibility that is supported by the 
results of our sensitivity analysis which indicated a stronger association similar to earlier results 
(3, 4), is that there may have been misclassification of the outcome in our analysis. It is possible 
that cytological abnormality detected by Pap smear (the primary outcome of interest) may not 
have reflected HPV–related cellular changes in all cases. Unfortunately, despite the suggestion of 
an association, we had limited power to detect a statistically significant association in HIV 
positive women and were unable to run multivariate analysis in HIV negative women.  Taken 
together, these findings suggest that cocaine may be associated with HPV-associated clinical 
outcomes, but not cytological abnormalities without HPV.  
 The high prevalence of abnormal Pap results without concurrent HPV infection in our 
main analysis may be related to the older age of our study population; the ALIVE cohort is aging 
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with a median age of participants of 39 years at study entry. Results from the ATHENA study 
(14-16) and Kaiser study (17-19) support an age-related decrease in concordance of HPV 
positivity and Pap abnormality. In addition, an inverse association between the prevalence of a 
high-risk HPV infection among ASCUS Pap results and increasing age has been previously 
reported, where 74% of ASCUS results in women under 30 years were HPV positive and 19% in 
women 50 years and older, suggesting a distribution shift by age (20). An age effect on 
distribution of cytological abnormalities is also supported by biological mechanisms suggested to 
explain the increased incidence of cellular abnormalities with age, including immune senescence 
associated with aging and regression of the cervical transformation zone into the os in older 
women (17). Hormonal changes with increasing age may also elevate abnormal cytological 
findings and produce artifacts that resemble HPV effects (21, 22). Our data may provide further 
support to this hypothesis that cytological abnormalities detected by Pap smear in older women 
may represent morphological changes not associated with risk of HPV-associated cervical cancer. 
 This study has some limitations. First, we had limited power when restricting the 
outcome to HPV-associated cytological abnormalities. We were powered to detect an association 
of 1.6 for the 277 women in the overall analysis, but this power was attenuated in the sensitivity 
analysis with only 190 women, particularly among HIV negative women. While our results were 
suggestive of an association between crack/cocaine use and HPV positive Pap abnormalities, we 
cannot draw definitive conclusions because of small sample size and inability to perform 
multivariate analysis among HIV negative women. Secondly, measurement of Pap abnormality at 
semiannual visits (typically six months apart or longer) is an interval censored survival outcome 
(23), which could lead to missed HPV-associated transient cytological changes since a large 
proportion of ASCUS results are known to spontaneously regress in young, healthy women (24). 
As a result, our ability to detect any true association of crack/cocaine with clinically-detectable 
HPV-associated disease may have been limited, though the clinical relevance of these transient 
abnormalities is uncertain. Third, we acknowledge that exposures were self-reported by study 
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participants.  While sexual and drug risk behaviors may be subject to reporting bias, we believe 
that the long-term nature of the parent study and rapport built between participants and study staff 
over time, as well as use of computerized methods to collect sensitive information in recent years, 
minimizes the possibility of this bias. Fourth, the population of current and former drug-using 
women included in this study is representative of chronic drug-using women in an urban 
community with high poverty rates and may not be representative of drug-using women in the 
overall United States. However, any biological mechanism underlying the purported association 
between cocaine use and cytological abnormalities should not be unique to urban-dwelling, drug-
using women. 
 This study also has several strengths. To date, there are few studies focusing on 
crack/cocaine as a potential direct cause of HPV-associated clinical abnormalities. Using existing 
data, we highlighted the presence of and potential impact of non-HPV-associated abnormalities 
on analyses of Pap outcomes among older women. This study draws strength from the 
longitudinal design of a well-established parent study(7) and considerable increase in follow-up 
time, over 18 years, compared to previous analyses. Additionally, this community-based parent 
study gives a more accurate picture of the experience of women who do not necessarily have 
access to health care (but are referred to care as part of this study) and use cocaine. 
 In summary, we did not identify a clear association between recent cocaine use and 
incident cervical cytological abnormalities among a community-based cohort of HIV-infected and 
–uninfected drug-using women. This highlights the need for additional studies to utilize a better 
measure of HPV-associated cytological abnormality and an even larger population of HIV-
uninfected cocaine-using women to elucidate any cocaine-associated effect on clinically-
detectable HPV infection. Further, due to the known immune suppression associated with HIV 
infection and the high prevalence and incidence of abnormal cytology among HIV-infected 
women(25, 26), future work among drug-using populations with and at-risk for HIV should 
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stratify by HIV status to remove the strong effect of HIV on analyses of immune-system-related 
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Table 1. Index Visit Characteristics of 277 Female Participants by Recent Cocaine or Crack 




Any cocaine  
or 
 crack use 
 
Total p-value* 
Characteristic N % N %   N 
       
Total 114 41.0 163 59.0 277  
       
Demographics       
       
Age category (years)       
<35 28 24.6 46 28.2  74 0.20 
35-39 33 29.0 55 33.7 88  
40-45 21 18.4 34 20.9 55  
>45 32 28.1 28 17.2 60  
       
Race       
White 9 7.9 4 2.5 13 0.13 
Black, non-Hispanic 101 88.6 153 93.9 254  
Black, Hispanic 2 1.8 5 3.1 7  
Asian 2 1.8 1 0.6 3  
       
Cohort (year enrolled)       
10,000s (1988-1989) 77 67.5 127 77.9 204 0.18 
70,000s (1994-1995) 20 17.5 15 9.2 35  
80,000s (1998) 8 7.0 6 3.7 14  
20,000s (2000-2001) 6 5.3 10 6.1 16  
30,000s (2005) 3 2.6 5 3.1 8  
       
Clinical/Immunologic Characteristics      
       
Body Mass Index, kg/m2       
Underweight, <18.5 4 3.5 14 8.6 18 <.0001 
Normal weight, 18.5-24.9 39 34.5 101 62.4 140  
Overweight, 25-29.9 38 33.6 28 17.3 66  
Obese, ≥30 32 28.3 19 11.7 51  
       
HIV serostatus / CD4 category       
Uninfected 39 34.2 50 30.7 89 0.24 
HIV+, CD4 >500 32 28.1 34 20.9 66  
HIV+, CD4 200-500 29 25.4 47 28.8 76  










Characteristic N % N % N  
       
Prior antiretroviral therapy       
No 44 59.5 68 60.2 112 0.92 
Yes 30 40.5 45 39.8 75  
       
Prior AIDS diagnosis       
No 85 74.6 105 64.4 190 0.07 
Yes 29 25.4 58 35.6 87  
       
Behavioral Risk Factors       
       
Cigarette smoking       
No 15 13.2 11 6.7 26 0.07 
Yes 99 86.8 152 93.3 251  
       
Any sexual intercourse       
No 39 34.2 59 36.2 98 0.77 
Yes 74 64.9 104 63.8 178  
       
Sexual intercourse with IDU       
No 84 77.8 93 59.6 177 0.002 
Yes 24 22.2 63 40.4 87  
       
Sexual intercourse with 
anonymous partner 
      
No 107 99.1 143 91.7 250 0.0096 
Yes 1 0.9 13 8.3 14  
       
Number of male sexual partners       
0-2 110 99.1 144 88.9 254 0.0017 
3-7 1 0.9 15 9.3 16  
>7 0 0 3 1.9 3  
       
Sexually Transmitted 
Infections‡ 
      
No 104 91.2 135 83.3 239 0.06 
Yes 10 8.8 27 16.7 37  










Characteristic N % N % N  
       
Substance Use Behavior       
       
Injection drug use        
No 111 83.5 22 8.5 133 <.0001 
Less than daily 15 11.3 96 37.2 111  
At least daily 6 4.5 138 53.5 144  
       
Marijuana use       
No 98 86.0 106 65.0 204 <.0001 
Yes 16 14.0 57 35.0 73  
       
Heroin use       
No 97 85.1 15 9.2 112 <.0001 
Yes 17 14.8 148 90.8 165  
       
Shared needles       
No 113 99.1 114 70.9 227 <.0001 
Yes 1 0.9 49 30.1 50  
       
Notes: Characteristics refer to the six-month time period prior to baseline visit, unless otherwise 
mentioned. ASCUS=Atypical Squamous Cells of Undetermined Significance; LSIL=Low-grade 
Squamous Intraepithelial Lesions; HSIL=High-grade Squamous Intraepithelial Lesions; 
IDU=Injection Drug Use. 
Percentages may not sum to 100% due to missing observations and/or rounding. 
 
* p-values are based on chi-square test for categorical variables or Fisher’s exact test for variables 
with cell values less than five. 
 
† HPV type ascertained on a subset of women who provided cervicovaginal lavage specimens for 
a separate substudy (227 missing values at baseline visit). 
 
‡ STIs reported do not include Chlamydia. 
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Table 1a. Cervical Cytology and HPV Type Status of Female Participants by Recent Cocaine or 
Crack Cocaine Use at Index Visit, The AIDS Linked to the Intravenous Experience (ALIVE) 
study 
No cocaine  
or  
crack use 
Any cocaine  
or 
 crack use Total p-value* 
Characteristic N (%) N (%)  
       
Total 114 41.0 163 59.0 277  
       
Incident Pap abnormality       
No 101 88.6 138 84.7 239 0.35 
Yes 13 11.4 25 15.3 38  
       
Pap smear result       
Normal 101 88.6 138 84.7 239 0.39 
ASCUS 7 6.1 19 11.7 26  
LSIL 3 2.6 4 2.5 7  
HSIL 3 2.6 2 1.2 5  
       
HPV type detected†       
Oncogenic 8 44.4 14 43.8 22 0.96 
Non-oncogenic 10 55.6 18 56.3 28  
       
Notes: Characteristics refer to the six-month time period prior to baseline visit, unless otherwise 
mentioned. ASCUS=Atypical Squamous Cells of Undetermined Significance; LSIL=Low-grade 
Squamous Intraepithelial Lesions; HSIL=High-grade Squamous Intraepithelial Lesions; 
IDU=Injection Drug Use. 
 
Percentages may not sum to 100% due to missing observations and/or rounding. 
 
* p-values are based on chi-square test for categorical variables or Fisher’s exact test for variables 
with cell values less than five. 
 
† HPV type ascertained on a subset of women who provided cervicovaginal lavage specimens for 




Table 2. Odds ratios (OR) and 95% confidence intervals of incident cervical cytological 
abnormality for any recent crack/cocaine use from logistic regression with generalized estimating 
equations (GEE) in 277 women, The AIDS Linked to the Intravenous Experience (ALIVE) study  




 Visits Women OR     95% C.I. OR  95% C.I. 
      
Unadjusted Model      
      
Overall cohort 1864 277 Ref 1.23 0.93-1.63 
Among HIV-Negative 810 89 Ref 1.78 0.95-3.34 
Among HIV-Positive 1054 198 Ref 1.09 0.77-1.54 
      
Adjusted Model (adjusting for age, self-reported history of sexually transmitted infections, 
cigarette smoking, body mass index) 
      
Overall cohort 1844 276 Ref 1.06 0.79-1.44 
Among HIV-Negative 800 89 Ref 1.29 0.65-2.57 
Among HIV-Positive 1044 197 Ref 1.01 0.69-1.48 
      
  
82 
Table 3. Odds ratios (OR) and 95% confidence intervals of incident HPV-positive cytological 
abnormality for any recent crack/cocaine use from logistic regression with generalized estimating 
equations (GEE) in subset of 190 women with HPV genotype testing, The AIDS Linked to the 
Intravenous Experience (ALIVE) study 




 Visits Women OR     95% C.I. OR  95% C.I. 
      
Unadjusted Model      
      
Overall cohort 625 190 Ref 1.85 0.93-3.66 
Among HIV-Negative   Non-estimable* 
Among HIV-Positive 367 126 Ref 1.58 0.78-3.21 
      
Adjusted Model (adjusting for age, self-reported history of sexually transmitted infections, 
cigarette smoking, body mass index) 
      
Overall cohort 620 190 Ref 1.42 0.71-2.85 
Among HIV-Negative   Non-estimable* 
Among HIV-Positive 365 126 Ref 1.41 0.66-2.99 
      
 
*There were zero outcomes observed among 101 visits among non-crack/cocaine-using, HIV-
seronegative women. We observed five outcomes out of 157 visits (3.18%) among crack/cocaine-
using HIV-seronegative women. In contrast, among HIV-seropositive women, we observed 
13/142 outcomes (9.15%) among non-crack/cocaine-users and 31/225 outcomes (13.78%) among 








Synthesis of evidence 
Current Evidence 
Current understanding of the natural history of human papillomavirus (HPV) 
infection involves the virus’ ability to evade the host immune system and replicate, 
typically resulting in a transient infection when immunity is intact (1). The role of host 
immunity is critical in controlling HPV replication and preventing development of 
detectable cervical precancerous lesions (2, 3). However, other risk factors have been 
identified as being associated with increased risk of HPV infection and related outcomes 
including cervical lesions and cervical cancer; these include sexual risk behavior, illicit 
drug use, and dampened immune response (2). In addition, there is growing evidence that 
drug use, especially use of crack/cocaine, may be associated with increased risk of HPV 
and cervical cancer through an immunologic mechanism (4-6) independently from shared 
sexual risk. Prior epidemiologic research has not focused on characterizing the potential 
risk associated with cocaine use as an immune-dampening exposure and the potential 
impact of cocaine use on HPV infection; the work described in this dissertation examines 
the hypothesis that cocaine use is associated with HPV-associated clinical outcomes 
through an immunologic mechanism.  
Cocaine use and Clinically Detectable HPV Infection 
To examine the potential association between cocaine use and HPV infection, we 
focused on clinically detectable infections, observable as abnormal Pap results of atypical 
squamous cells of undetermined significance (ASCUS) or more severe cytological 
abnormality among HIV-infected and uninfected women in an urban community-based 
cohort followed over 18 years. We observed a positive association between recent 
 85 
cocaine use by any route of administration and risk of incident cervical cytological 
abnormality in the overall cohort. The association is likely driven by the risk among HIV-
infected women, which comprise a majority of the analytic cohort (70%), since there are 
no observable outcomes in HIV-infected women who have intact immune systems 
(Chapter 3). While prior research has established a positive association between drug use 
and HPV infection among cohorts of HIV infected and uninfected women (7, 8), our 
findings did not achieve statistical significance. With zero HPV clinical outcomes 
detected among uninfected women, we were unable to examine this potential association 
in a setting independent from the immunosuppressed state caused by HIV infection. 
Despite this limitation, some comments can be made. The lack of events observed among 
uninfected women in this population was likely due to the reduced sample size and low 
risk of HPV-clinical outcomes in this immune competent population, which might be 
interpreted as the expected occurrence of abnormality among populations with an intact 
adaptive immunity and no exposure to immune-modulating cocaine. However, we did 
observe a moderate association in the hypothesized direction of increased risk among 
drug-using HIV-infected women (OR=1.41, 95% C.I.: 0.66-2.99), which lends support 
for the possibility that cocaine use is truly associated with increased risk of HPV-related 
outcomes.  
Cocaine-induced Immune Suppression 
We proposed that the known association between cocaine and HPV infection may 
occur through a hypothesized mechanism by which cocaine elicits an immunosuppressive 
response in drug users. Since an HPV-specific adaptive immune response is critical to 
lesion regression (9), it is possible that cocaine use causes immune dampening which 
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may result in uncontrolled HPV replication. Additional evidence supporting this 
mechanism is provided in a different cohort of at-risk HIV-positive and HIV-negative 
women throughout the United States, the Women’s Interagency HIV Study (WIHS). In a 
subset of the overall WIHS cohort followed prior to the broad usage of highly active 
antiretroviral therapy (HAART), we observed statistically significant evidence of reduced 
adaptive immune response at the epithelial cell level among HIV-uninfected cocaine 
users (Chapter 2). Since HPV is an exclusively intraepithelial infection (9), our findings 
provide additional support for plausibility of a biological mechanism where cocaine-
induced immune suppression may increase the risk of HPV-associated clinical outcomes.  
Differential Anergy Results Among HIV-Infected and Uninfected Women 
Interestingly, we observed a positive association between cocaine use and local 
epithelial immune response only among HIV-uninfected women in the WIHS. Among 
women with HIV infection, cocaine use was not associated with anergy in either 
unadjusted (ORunadj 1.03, 95% C.I.: 0.80-1.34) or adjusted analyses (ORadj 1.08, 95% 
C.I.: 0.78-1.50). It is plausible that any cocaine-induced immune dampening may be 
masked by overwhelming HIV-associated systemic immune suppression, resulting in the 
contrasting results we observed between HIV-infected and uninfected populations. In our 
analytic cohort, the 277 HIV-infected women displayed characteristically low systemic 
immunity indicated by a median CD4 cell count of 391 (IQR: 207-612), while uninfected 
women had higher cell counts (median 1,007, IQR: 818-1,341) reflecting intact 
immunity. Examining associations among HIV-infected and uninfected populations 
separately likely enabled this association to be elucidated among uninfected women, if 
this mechanism is indeed true. In unadjusted analysis of the cocaine-anergy relationship 
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among WIHS women, those with very low CD4 cell counts (less than 200 cells/mm3) 
were more likely to be anergic compared to those with higher CD4 counts (Chapter 2, 
Table 2). Results from the bivariate analyses among HIV-infected women, where anergy 
was found to be associated with overall systemic immune suppression, provide additional 
evidence that cocaine’s effect on anergy may be washed out by HIV-associated immune 
suppression. In future work, stratification by CD4 cell count would be pertinent to 
examine systemic immune influences on the cocaine-anergy relationship, but 
unfortunately, we were underpowered to do so in these analyses. 
Cocaine and Other Illicit Drug Use  
An additional challenge in attempting to isolate the effect of one drug exposure 
use is that cocaine is commonly used in combination with other illicit drugs. In the 
ALIVE cohort, we found that 65% of the women who reported cocaine use injected a 
combination of cocaine and heroin (also known as “speedball” injection), highlighting the 
difficulty of disentangling the effects of cocaine from heroin and other drugs. In the 
WIHS, we also observed a high level of combined drug use: 40% of recent cocaine users 
also reported using heroin within the last six months and half of cocaine users also used 
marijuana. In terms of psychoactive effects, cocaine is a stimulant while heroin is a 
depressant, yet each dampen immune responses. Opiates like heroin have been suggested 
to have indirect immunomodulatory effects through interactions with the neuroendocrine 
system(10, 11) as opposed to the direct effect of cocaine on cytokines and immune 
cells(5, 12, 13). Teasing apart the effect of a single drug type presents a challenge since 
exposure to either drug results in immune response suppression in animal (14-16) and 
 88 
cell line models (17). Given the similar immune effects, we would expect to observe 
additive risk of immune reductions among combination drug users.  
Applying this logic to our ALIVE analyses, we would have expected that any 
combination drug use in addition to cocaine would be likely to inflate the overall 
observed association, since increases in the risk of immune suppression would be 
expected with multiple immune-suppressive drug exposures, subsequently allowing for 
increased HPV persistence. However, when we examined the effect of exposure to both 
cocaine and heroin on risk of any incident cervical cytological abnormality compared to 
use of cocaine only, we did not observe any notable differences in effect size between the 
resulting risk estimates in the ALIVE cohort (data not shown). Benefitting from available 
data on recent use of a variety of illicit drugs, our research was able to account for other 
types of drugs used including marijuana and heroin. In this dissertation, we focus on a 
single drug type; however, we emphasize that use of any immune-suppressive drug may 
be a contributing risk factor for HPV persistence and associated disease.  
Role of sexual risk behavior on observed associations 
Existing published literature suggests that shared sexual risk behavior accounts 
for the increased risk of HPV-related disease among drug-using populations by 
increasing exposure to HPV infection (8, 18). However, there is evidence that sexual risk 
alone may not explain the entire association; in the control arm of a quadrivalent HPV 
vaccine efficacy study, incident HPV detection was observed among recently non-
sexually active participants (19). Additionally, in a previous, smaller study among HIV-
uninfected women in one of our cohorts (ALIVE), accounting for sexual risk behavior 
did not attenuate risk estimates for crack/cocaine use and HPV-related outcomes (7). In 
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our expanded study on ALIVE women followed for nearly two decades, indicators of 
recent sexual risk including number of male sexual partners and high-risk sexual 
intercourse similarly did not have a notable impact on the observed association between 
cocaine use and incident HPV-positive abnormal Pap results. As a result, the only sexual 
risk factor retained in the multivariate adjusted model was self-reported history of 
sexually transmitted infections (STIs), which may be a marker of previous exposure to 
HPV rather than purely reflective of recent sexual risk behavior. Furthermore, adjustment 
for history of STIs along with other potential confounders resulted only in a slight 
attenuation of the risk estimate among HIV-infected women, OR=1.58 vs. 1.41, with the 
same positive direction of association retained. In our research, we did not find evidence 
for confounding by sexual risk, nor did sexual risk factors play a substantial role in 
dampening the magnitude of observed effect size. Therefore, we cannot conclude that 
sexual risk behavior explains much of the increased risk of HPV-associated 
abnormalities, and, fittingly, our findings do not rule out an alternate mechanism of 
cocaine-induced genital tract immune suppression.  
Conclusion 
In this research using data from ALIVE and WIHS women, we hypothesized that 
local epithelial immune suppression directly related to cocaine exposure may allow for 
HPV infection to proliferate and manifest as clinically detectable cellular changes in 
cervical epithelial tissue. Even though our findings were not definitive, this work is 
persuasive in calling attention to the potential contribution of cocaine use to local 
immune suppression and the subsequent impact on HPV natural history. While we were 
unable to show conclusive evidence for this purported association among HIV-infected 
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women due to power constraints, our findings do suggest that an immune suppressive 
effect of cocaine use may be real. Besides our study, the association between cocaine use 
and HPV infection has only been previously examined in two studies which have 
identified associations between recent crack/cocaine use and new HPV detection (OR, 
1.7; 95% CI, 1.1-2.6) (7), prevalent detection of oncogenic HPV (OR, 1.30; 95% C.I.: 
1.09-1.55), prevalent detection of oncogenic HPV-positive SIL (OR, 1.70; 95% C.I.: 
1.27-2.27), and a non-statistically significant risk of incident oncogenic HPV-positive 
SIL (HR, 1.51; 95% CI 0.99-2.30) (8). Our findings, in conjunction with these previous 
studies, provide growing epidemiologic evidence for a biological mechanism of cocaine-
induced immune compromise which has the potential to increase risk of HPV persistence 
and, more rarely, progression to cervical cancer. 
Limitations 
 We recognize that our results may not be generalizable to all women who use 
cocaine or crack cocaine, since cocaine use may not have a clinically relevant effect 
among severely immune compromised HIV-infected women. Despite this, we believe it 
is plausible that a biological effect of cocaine-associated suppression of immune response 
to HPV infection would be similar among other immune competent drug-using 
populations. Since recruitment methods from ALIVE enrolled participants directly from 
the community, inferences drawn from data from the ALIVE study on cocaine use and 
abnormal Pap outcomes may be generalizable to similar injection drug users (IDUs) in 
Baltimore; however, since IDU practices have been reported to differ by urban 
location(20), we may not be able to generalize our findings to other drug-users in 
different areas. Nevertheless, since we believe that a biological mechanism of immune 
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suppression underlies the association observed between cocaine use and HPV-associated 
lesions, we would not expect this mechanism to differ across geographic areas and we 
believe our findings may be generalizable to cocaine-exposed women. In addition, the 
data available on anergy test results were collected between 1994 and 1996; while this is 
data is not current, the biological mechanism we are interested in has likely not changed 
over time. 
Our findings may also be limited by the timing of measurement of the HPV-
associated clinical outcomes since a large proportion of ASCUS results are known to 
spontaneously regress in young, healthy women(21). In the ALIVE, measurement of Pap 
outcomes at semiannual visits occur typically at six month intervals, or even longer as 
visits are often missed among drug using populations. Measuring this interval-censored 
survival outcome(22) could theoretically lead to missed HPV-associated transient 
cytological changes. It is possible that, as described, non-differential misclassification of 
outcome may have limited our ability to detect a true association of crack/cocaine and 
increased risk of HPV disease. Similar to other cohort studies employing semi-annual 
visits, this study design did not allow for measurement of outcomes at shorter time 
intervals due to logistical constraints and undue burden on participants. For this analysis, 
we focused on clinically detectable cervical cytological changes to reflect increased risk 
of progression to cervical cancer. Including minimally abnormal Pap results (e.g., 
ASCUS) in the outcome definition may have inappropriately captured typically transient 
changes that may not correlate with cervical cancer risk. Nevertheless, we believe that 
measuring Pap results at extended intervals ensures that positive outcomes reflect HPV 
infection that has persisted long enough to cause clinically detectable changes. Thus, our 
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results should be relevant when interpreted as the cocaine-associated risk of HPV disease 
progression. 
Throughout these analyses, measures of exposure and various covariates were 
assessed through participant self-report. We have no data on biological measures to 
confirm these self-reported data on drug use; however, behaviors are reported using audio 
computer-assisted self-interviewing (ACASI) in the ALIVE cohort, which has been 
shown to improve disclosure of illicit drug use and HIV-related risk behaviors (23, 24). 
In addition, self-reported drug use practices have been validated in other similar natural 
history studies, as well as a review (24-26). If drug users were systematically 
underreporting use of cocaine due to social desirability bias, then we would expect that 
any associations observed would be biased towards the null. Therefore, our findings 
would reflect a conservative estimate of the association between cocaine use and HPV-
related clinical outcomes.  
Strengths 
Our research using data from two different cohorts provides initial evidence in 
support of drug-induced immune suppression as a mechanism for loss of immune control 
of HPV infection. The interdisciplinary nature of linkages between illicit drug use 
behavior, basic science mechanisms, HPV viral persistence and replication, cervical and 
mucosal immunology, and clinical measures of our outcomes were drawn together in this 
research to better understand the complex nature of HPV natural history and cocaine use.
We benefit from having high quality data from which to draw inferences by studying 
these associations in two prospective cohorts followed for many years. These longitudinal 
studies have successfully recruited and retained populations who are difficult to identify, 
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and are robust sources of sensitive information on drug use and sexual risk behavior that 
are challenging to collect. Additionally, our studies focused on populations that are 
poised to benefit from focused research attention; the ALIVE population is 
predominantly African-American and represents an understudied group, while both 
WIHS and ALIVE provide data that reflect the real-world experience of drug-using 
women(20, 27) who represent a vulnerable population. 
Our findings are novel because we provide initial epidemiologic support to build a 
case for the hypothesis that clinically detectable HPV outcomes may be partially 
explained by drug-induced anergy. We utilized existing cohort data to directly assess the 
association between cocaine use and cutaneous anergy, and explore whether cocaine use 
is associated with increases in clinical evidence of HPV replication (i.e., SIL). By 
focusing on clinically relevant outcomes, we hope to ensure that our results are applicable 
to clinical management of these vulnerable populations.  
Public health significance 
In the United States, an estimated 14.9 million females report any cocaine use in 
their lifetime and 1.37 million women used cocaine in the past year based on 2012 data 
(28). Despite the large size of this drug-using population, the impact of cocaine use on 
HPV natural history has not been well studied. Since cervical cancer is preventable, there 
is substantial benefit that can be achieved with identification of populations at higher risk 
for HPV-associated disease, specifically those at risk due to immune suppressive effects 
of cocaine use. Current cervical cancer guidelines do not specify differential screening 
practices based on drug use, but have recently suggested more frequent screening among 
HIV-infected and immune compromised populations (29). Given our findings, a more 
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thorough understanding of cocaine-associated HPV risk could potentially support 
clinicians and public health professionals to continue work towards achieving adequate 
cervical pre-cancer surveillance among cocaine-using populations and inform appropriate 
clinical management of HPV infection among women who use drugs. 
Improved understanding of the role of HPV infection in cervical cancer risk and 
the potential impact of cocaine use on HPV disease risk among drug users may lead to a 
desire to mitigate risk of cervical cancer by participating in enhanced surveillance or 
reducing drug use. Community outreach opportunities including health education among 
drug users to increase knowledge of HPV risk (30) may be implemented to encourage 
risk reduction among cocaine-using women. In addition, these findings may guide public 
health programs to consider focusing efforts on supporting drug cessation in addition to 
health education to reduce risk of HPV-associated disease.  
The results from our studies indicate that cocaine-associated immune suppression 
may play an important role in HPV natural history in these exceptionally vulnerable 
populations. Enhanced understanding of the nature of and risk related to replicative HPV 
infection may also help public health professionals to target and plan interventions for 
reducing HPV transmission by drug-using core groups with active HPV infection.   
Future work 
Current gaps in knowledge surrounding HPV natural history include the need to 
identify markers of reduced immunity and correlates of HPV-associated disease 
outcomes (31). In our work, we used cutaneous anergy as a proxy measure of epithelial 
immune response at the cervix. It would better address HPV-specific research questions 
if future studies had a specific marker or measure of mucosal epithelial immunity at the 
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cervical endothelium, the preferred target for HPV infection(32), to minimize potential 
for bias.  
Our work highlights opportunities where future research may help clinicians and 
public health professionals caring for women who use drugs by improving risk 
stratification for those at risk for HPV-associated outcomes. A more thorough 
understanding of the complex relationship between cocaine use, immune-suppression, 
and HPV disease could be gained through larger prospective studies of HIV-uninfected 
populations who use cocaine. We would also benefit from studies in which measures of 
cocaine exposure, HPV-specific immune markers, and HPV outcomes are taken within in 
the same cohort in order to examine the role of immune suppression as a mediator of the 
association between cocaine use and HPV-related disease.  
To gain a better understanding of the cocaine-mediated pathway of local immune 
suppression, future work should explore additional specifications of exposure, including 
intermittent cocaine use compared to long-term or other patterns of drug use. Such 
studies may elucidate if varying patterns of use differentially affect immune responses, 
specifically control of HPV infection and subsequent clinical sequelae. However, we 
acknowledge that such studies but would require large populations with detailed data on 
drug use dosage, frequency, and usage patterns followed for a long period of time in 
order to be sufficiently powered to examine these additional refinements to the exposure-
outcome relationship.  
We learned from our analyses that interpreting cervical abnormalities detected on 
Pap smear in an aging population of women is challenging. Abnormal Pap results may 
not always reflect HPV infection and may simply signify age-related changes(33, 34). 
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With this in mind, understanding cocaine-associated risk for HPV-associated disease 
could also benefit from research using HPV DNA testing for outcome measurement, 
which is a more sensitive test than the Pap smear for detecting cervical intraepithelial 
neoplasia (35, 36). In addition, HPV genotype may be better correlated with cervical 
cancer risk than cytology (37), as high-risk HPV types have been associated with 
increased likelihood of persistence and progression to cervical cancer (38). Thus, using 
HPV genotype to define outcome may be better for making inferences about cervical 
cancer risk, which is the ultimate goal for prevention. Additionally, data on specific HPV 
genotype may enable further stratification of cocaine users by high- and low-risk HPV 
groups, resulting in tailored screening programs and adapted clinical management among 
drug users.  
Studies that collect and validate HPV genotypes detected over time could also 
contribute to distinguishing between existing and new infection. By doing so, this may 
improve understanding of the potential impact of cocaine on immune control of latent 
HPV infection, which may be identified as an existing genotype that becomes 
undetectable and is subsequently re-detected. It is possible that additional findings 
supporting cocaine-associated immune effects on HPV would generate supporting 
evidence for the hypothesized latent state of HPV infection (39), which could then lead to 
changes in the current understanding of HPV natural history. However, such studies 
would be difficult to conduct as frequent follow-up with intervals that allow adequate 
capture of potentially transient outcome measures would require vast resources and high 
adherence, which may be difficult to achieve in drug-using populations.  
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Results from our research using data from the ALIVE and WIHS cohorts of HIV-
infected and -uninfected women contribute evidence to support the possibility that 
cocaine use may induce immunosuppressive effects that impact persistence of HPV 
infection among otherwise immune competent women. Future research targeting this 
knowledge gap will help to better understand the cocaine-induced mechanism of 
immune-mediated alterations in HPV natural history. These proposed studies will be 
critical for improving strategies for risk stratification and prevention of cervical cancer 
among drug-using populations. More importantly, improved understanding of drug-
induced local immune suppression will contribute to a larger scientific body of 
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